

Hybrid Spring Group Meeting



Welcome (Back)!

I t has been two and one-half years since we last met face to face at a SWOG group meeting!

I'm thrilled to again have a chance to sit across the table from you rather than across the country, doing so in a way to minimize our risk from COVID-19.

This is SWOG's first truly "hybrid" group meeting. This simply means all sessions will also have a virtual component. All will be streamed live, and in many sessions, virtual participants will be able to submit questions or comments via a chat function.

I want to extend a particular thanks to those who have probably physically traveled farthest to be here – our colleagues from Central and South America. A face-to-face SWOG Latin America Initiative Symposium will be a high point of our meeting.



Other special events include a symposium on how oncology advanced practice providers can (and do!) contribute to SWOG research, and a special session on diversity, equity, and inclusion in genitourinary oncology (which has registered more than 100 attendees).

And then there are our plenary sessions. Our translational medicine plenary (Plenary I) will feature a progress report on some TM work supported by Hope Foundation grants and updates on TM in GU oncology and on working with CIMACs (Cancer Immune Monitoring and Analysis Centers). In Plenary II, after my updates on the state of SWOG, we'll hear progress reports on our truly important myeloma, GU, and NCORP research.

I'm really looking forward to seeing all of you in person once again. Welcome to Seattle!

A handwritten signature in black ink that reads "Charles D. Blanke, MD". The signature is written in a cursive, flowing style.

Charles D. Blanke, MD
SWOG Chair

Group Meeting Index

| | |
|---|-------------|
| Chair's Welcome Message | 2 |
| What is a Hybrid Meeting | 4 |
| Plenary Sessions | 5 |
| Special Sessions | 6-9 & 18-19 |
| CME Credit Information | 10-11 |
| Health & Safety | 12-13 |
| Top Accruers | 14 |
| Hotel Maps and Information | 16-17 |
| Schedule of Events | 20-23 |
| Upcoming Funding Opportunities | 24 |
| SWOG Administrative and Research Support Committees | 24 |
| Future Meeting Dates | 24 |
| Committee Agendas and Accrual Reports | |
| Barlogie-Salmon Myeloma Committee | 25-27 |
| Breast Committee | 28-32 |
| Cancer Control & Prevention Committee Leadership | 33 |
| Cancer Care Delivery Committee | 34-36 |
| Cancer Survivorship Committee | 37-38 |
| Early Therapeutics & Rare Cancer Committee | 48-52 |
| Gastrointestinal Committee | 53-59 |
| Genitourinary Committee | 60-67 |
| Leukemia Committee | 68-71 |
| Lung Committee | 72-77 |
| Lymphoma Committee | 78-83 |
| Melanoma Committee | 84-87 |
| Palliative & End of Life Care Committee | 39-40 |
| Prevention & Epidemiology Committee | 41-43 |
| Symptom Control & Quality of Life Committee | 44-47 |
| SWOG Publications | 88-94 |

Just What Is a “Hybrid” Meeting?

SWOG’s first 85 or so group meetings were face-to-face affairs. With the arrival of COVID-19, we conducted our last four group meetings entirely virtually. This time around, we’re taking a middle route — the hybrid meeting.



This means all meeting sessions will be held in person in Seattle but will also be accessible everywhere via Zoom.



Zoom links to all open meetings are posted on the virtual meeting page on the SWOG website. Zoom links to closed, invitation-only meetings will be emailed directly to those invited.



Each room will have a presentation laptop with a projector and screen. Virtual presentations by remote presenters will be visible on the projector screen to those in the room.



All presenters will have their slides displayed in the Zoom meeting interface. Virtual attendees will view them via Zoom, while in-person attendees will view them on the projector screen.



Audio will be two way as needed. For virtual presenters, the Zoom audio will be amplified for the room. For in-room speakers, audio from microphones will be fed into Zoom.



For many sessions, virtual attendees can post questions for the presenters using the Zoom chat feature. In these sessions, a moderator will monitor the chat.



All sessions will be recorded, and recordings will be available to attendees.

Meeting Plenary Sessions

Plenary I

Thursday, April 7, 3:00 - 4:30 pm PT

This spring's translational medicine plenary will feature the following speakers and topics:



Welcome
and Introduction

Lee M. Ellis, MD, FASCO
SWOG Vice-Chair for
Translational Medicine
MD Anderson Cancer Center



Hope Award
Progress Update

Priyanka Sharma, MD
Univ of Kansas Cancer Center



Translational Medicine
in GU Cancers

David J. McConkey, PhD
Johns Hopkins University



CIMAC
Update

Ignacio I. Wistuba, MD
MD Anderson Cancer Center

Plenary II

Year of Progress: Myeloma, GU, and NCORP

Friday, April 8, 12:00 – 2:00 pm PT

Three SWOG leaders will report on their committees' most significant results and undertakings over the last year, perhaps with glimpses of the year to come. Presentations will be followed by brief Q&A sessions.



Chair's Welcome
and Update

**Charles D. Blanke, MD,
FASCO, FAWM**
SWOG Group Chair
OHSU Knight Cancer Institute



Myeloma
Research Updates

**Robert Z. Orlowski,
MD, PhD**
SWOG Myeloma Committee Chair
MD Anderson Cancer Center



Genitourinary
Research Updates

Ian M. Thompson, Jr., MD
SWOG Genitourinary
Committee Chair
Children's Hospital of San Antonio



NCORP
Research Updates

Dawn L. Hershman, MD, MS
SWOG Vice Chair for NCORP
Research
Columbia University

Both Plenary I and Plenary II will also be live-streamed via Zoom, and questions for speakers will be fielded both in person and via Zoom's text chat feature.

Friday, April 8 | 9 – 11 am PT

Symposium: Radiation Oncology: Targeting Oligometastatic Disease in GU Cancers

The symposium will cover the use of radiosurgery for metastatic genitourinary cancers. Presentation topics will include



defining oligometastatic disease



considerations when integrating systemic therapy and radiation for metastatic cancer



radiomics of oligometastatic disease treatment



practical considerations



radiation plan quality assurance considerations

and much more.

PRESENTERS INCLUDE



• James Yu, MD



• Phuoc Tran, MD, PhD



• Abhishek Solanki, MD



• Chad Tang, MD



• Austin Kirschner, MD, PhD

• David McConkey, PhD



• Sanjay Aneja, MD



• TJ Fitzgerald, MD



• Bridget Koontz, MD



• Dan Hamstra, MD, PhD



THIS WILL BE AN INFORMATIVE SYMPOSIUM YOU WON'T WANT TO MISS!

Thanks To Our
CME Supporters!
We Value Their
Partnership


Lilly

AbbVie

AstraZeneca

Exact Sciences

Novocure



Wednesday, April 6 | 3 – 5pm PT

TAKE ACTION Symposium:

American Indians, Ensuring Equity in Clinical Research

Presented by SWOG Recruitment & Retention Committee



Ronny A. Bell, PhD, MS

Dr. Bell is a member of the Lumbee tribe and is a professor of social sciences and health policy, associate director of community outreach and engagement, and director of the Office of Cancer Health Equity at Wake Forest.



Linda Burhansstipanov, MSPH, DrPH

Dr. Burhansstipanov is a member of the Cherokee Nation. She founded the Native American Cancer Research Corporation (NACR) and Native American Cancer Initiatives (NACI).



Daniel G. Petereit, MD, FABS, FASTRO

Dr. Petereit is a radiation oncologist and a PI of the Walking Forward Cancer Disparity Program. He has published on the establishment of trust within tribal communities.

Target Audience: Investigators, research professionals, and patient advocates, NCORP and LAPS


OBJECTIVES:

Identify evidenced-based practical strategies sites can use to ensure access and equity in SWOG clinical trials

Address cultural values of the specific population that support building trust

Review the current environment of the American Indian population that impacts trial participation

TAKE ACTION
Recruitment & Retention
Diversity, EQUITY, & Inclusion
Disparities Research Trust



Saturday, April 9 | 12 – 2 pm PT

Symposium: Diversity, Equity, and Inclusion in GU Oncology in SWOG

The SWOG GU committee will host an interactive symposium to develop goals and task forces to enhance diversity, equity, and inclusion (DEI) within the committee.

All are welcome to attend this symposium, GU committee members or not!

Panelists will share perspectives and experiences, but much of the time will be devoted to Q&A so members can share concerns and all can learn from each other's experiences.



Symposium moderators
Tanya Dorff, MD, City of Hope Comprehensive Cancer Center, and **Ulka Vaishampayan, MD**, University of Michigan




Rogel Cancer Center, will open the session with a brief overview of the characteristics of the GU committee membership and leadership.

PANELISTS

- **Chunkit Fung, MD**
University of Rochester & ASCO Sexual Minority Task Force
- **Joël Pointon**
SWOG patient advocate
- **Chanita Hughes Halbert, PhD**
Director, Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health, University of Southern California
- **Hayley Thompson, PhD**
Wayne State University
- **Desiree Walker**
SWOG patient advocate

Organizers would love for members of other committees to join the symposium!



Procedures for CME Credit

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following areas: Adolescent and Young Adult Committee; Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control & Quality of Life Committee, Prevention & Epidemiology Committee, Palliative & End of Life Care Committee, and Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee;

Lymphoma Committee; Immunotherapeutics Committee; Digital Engagement Committee; and Bone Marrow & Stem Cell Transplantation Committee

Continuing Medical Education Credit


The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. In addition, nurses, CRAs, and other researchers may be able to claim credits through their respective credentialing bodies.

The Hope Foundation designates this live activity for a maximum of 28.25 AMA PRA Category 1 Credits™. Learners should only claim credit commensurate with the extent of their participation in the activity.

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation — CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

We've gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits. Getting your credits online is easy:



Your certificate will automatically be emailed to you. Problems or questions?

Contact Courtney Wille in the SWOG operations office

at cwille@swog.org. To keep track of your credits during the meeting, use the form on the next page.

Track Your CME Credits

Instructions:

1. In the column labeled actual credit, please write in the amount of credit you are claiming for each meeting.
2. Then total the amount of credit you are claiming in the actual credit column. Return to cwille@swog.org. Your certificate will be emailed to you.

| Day/Time | Session Title | Credits | |
|---------------------------------|---|--------------|--------------|
| | | Available | Actual |
| WEDNESDAY, APRIL 6, 2022 | | | |
| 12:30 pm – 2:30 pm | Digital Engagement Committee | 2.0 | _____ |
| 4:30 pm – 6:30 pm | Immunotherapeutics Committee | 2.0 | _____ |
| THURSDAY, APRIL 7, 2022 | | | |
| 8:00 am – 10:00 am | Cancer Survivorship Committee | 2.0 | _____ |
| 10:00 am – 12:00 pm | Bone Marrow & Stem Cell Transplantation Committee | 2.0 | _____ |
| 10:00 am – 12:15 pm | Early Therapeutics and Rare Cancers Committee | 2.25 | _____ |
| 10:15 am – 12:15 pm | Cancer Care Delivery Committee | 2.0 | _____ |
| 5:00 pm – 7:00 pm | Palliative and End of Life Care Committee | 2.0 | _____ |
| FRIDAY, APRIL 8, 2022 | | | |
| 7:00 am – 9:00 am | Barlogie-Salmon Myeloma Committee | 2.0 | _____ |
| 7:30 am – 9:30 am | Symptom Control and Quality of Life Committee | 2.0 | _____ |
| 9:00 am – 11:00 am | Radiation Oncology: Targeting Oligometastatic Disease in GU Cancers | 2.0 | _____ |
| 9:00 am – 12:00 pm | Lymphoma Committee | 3.0 | _____ |
| 9:45 am – 11:45 am | Prevention and Epidemiology Committee | 2.0 | _____ |
| 12:00 pm – 2:00 pm | Plenary II (General) | 2.0 | _____ |
| 2:15 pm – 4:15 pm | Adolescent and Young Adult (AYA) Committee | 2.0 | _____ |
| 2:15 pm – 4:15 pm | Surgery Committee | 2.0 | _____ |
| 2:30 pm – 4:30 pm | Melanoma Committee | 2.0 | _____ |
| 3:00 pm – 5:00 pm | GI Committee | 2.0 | _____ |
| 3:15 pm – 6:15 pm | GU Committee Part I: Renal, Trans Med, Cancer Control | 3.0 | _____ |
| 3:30 pm – 6:30 pm | Breast Committee | 3.0 | _____ |
| SATURDAY, APRIL 9, 2022 | | | |
| 8:15 am – 10:15 am | Leukemia Committee | 2.0 | _____ |
| 8:30 am – 11:30 am | Lung Committee | 3.0 | _____ |
| 8:30 am – 11:30 am | GU Committee Part II: Bladder, Prostate | 3.0 | _____ |
| 12:00 pm – 2:00 pm | Diversity, Equity, and Inclusion in GU Oncology in SWOG | 2.0 | _____ |
| 12:00 pm – 2:00 pm | Radiation Oncology Committee | 2.0 | _____ |
| Total Possible Credits | | 28.25 | _____ |

SWOG Spring 2022 Hybrid Group Meeting: Health & Safety

In deciding to attend this meeting, you assume all responsibility for your own health and safety. Please wear a mask in indoor public spaces unless eating, drinking, or presenting. Extra masks are available at the registration desk.


Full Vaccination and Booster Shot Required

Many SWOG members work with immunocompromised patients every day.

The last thing they want is to bring a dangerous virus back with them after a trip to a meeting.

With this in mind, and given data showing reduced risk among those who have received a booster shot, SWOG requires that to attend the spring 2022 group meeting in person, you must be fully vaccinated (received all required doses of an FDA- or WHO-authorized two-dose or one-dose vaccine), and you must have received a vaccine booster shot prior to March 31.


The following are approved forms of vaccine verification. You must show one of these at the SWOG registration table when you pick up your name badge:



- ✓ **A CDC vaccine card** or photo of vaccine card
- ✓ **Printed certificate or digital record** from [MyIRMobile.com](https://myirmobile.com) (available in several states) or other apps
- ✓ **Documented proof** of vaccination from medical record or vaccine provider
- ✓ **QR code or digital copy** of your COVID-19 vaccination record from a system such as Washington state's WA Verify
- ✓ **Proof of vaccination** from your state or county

If you cannot or choose not to comply with the mandate, or if you are unable to travel to the meeting, please join us online for live-streamed sessions.

Free Rapid COVID-19 Tests



To help minimize the risk of spreading COVID-19 within SWOG group meeting venues, we are providing a rapid test kit to all attending members.

When you pick up your name badge, you will get a self-test kit (with 2 tests).

If you test positive for COVID-19 during the meeting, please consult the CDC website at <https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html> for guidance on how to reduce your chances of infecting others.

If you test positive and need additional rapid tests, have questions about hotel policy, or need help with changing your travel plans, please reach out to us at healthandsafety@swog.org.

We are here to help.



Thanks To

Our Top Accruers

Patient volunteers power our trials — and SWOG members connect us to them.

These members topped the charts for SWOG-credited registrations to SWOG managed trials in 2021.

We appreciate their hard work and their confidence in our research.

NCORP

Southeast Clinical Oncology
Research Consortium NCORP

Kaiser Permanente NCORP

Heartland Cancer Research NCORP

Cancer Research Consortium
of West Michigan NCORP

Gulf South Minority
Underserved NCORP

Main Member / LAPS

USC Norris Comprehensive
Cancer Center

University of Texas MD Anderson
Cancer Center

City of Hope Comprehensive
Cancer Center

University of Utah Huntsman
Cancer Institute

University of Rochester



A program of the National Cancer Institute
of the National Institutes of Health



a National Cancer Institute program


Support SWOG Today

Hope Funds Research, Education, and Group Meetings!

Whether through a cash donation made now, or a planned gift for the future, you can make a direct impact for our network and patients.

Thank you for your support of our shared mission to improve and lengthen lives.

thehopefoundation.org/donate



Support SWOG through planned giving

Your legacy gift will be an important part of imagining our shared future advancing clinical trials for patients everywhere.

Prefer the option of a stock gift?

Donating assets has never been easier using our online tool.


Learn more at thehopefoundation.org/donate

Or contact us about adding Hope to your estate plan

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

Hyatt Regency Seattle Floor Levels

808 Howell Street | Seattle, WA 98101 |
hyattregencyseattle.com | Phone: 206-973-1234



Seattle Travel & Hotel Information

808 Howell Street | Seattle, WA 98101 | hyattregencyseattle.com | Phone: 206-973-1234

Arrival/Departure:

Check-in time is **4:00 p.m.** Check-out time is **11:00 a.m.** Room amenities include a full bath, hair dryer, ironing board and iron, coffeemaker, refrigerator and in-room safe. The concierge staff serves as a liaison between guests and the hotel and outside services.

Hotel Safety Deposit Boxes:

For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

Recreational Facilities:

The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. It is open 24 hours a day. Reservations required.

Hotel Restaurants and Lounges:

- **Andare Kitchen & Bar:** Combines Italian flavors with fresh Seattle ingredients. Enjoy wood-fired pizzas, homemade pasta or salads

and signature desserts. Restaurant is located on the Lobby Level and is open Sunday – Thursday from 11:00 a.m. – 9:30 p.m. and Friday-Saturday from 11:00 a.m. – 11:00 p.m.

- **Daniel's Broiler Lounge:** The Rickhouse Whiskey Bar, located within Daniel's Broiler, features a wide selection of whiskey and other fine spirits from around the globe and TV's for viewing sports, all within a speak easy like setting. Lounge is located on the second floor and is open Tuesday – Saturday from 4:00 p.m. to close.
- **Market:** The Market has a selection of personalized espresso beverages, pastries, freshly prepared sandwiches and salads, hot entrees and more. Market is located on the second floor and is open daily from 6:30 a.m. – 11:00 a.m.

Business Center:

The Business Center is located on the second level. The Business Center offers fax machines, computer services, color copies, Internet access and photocopying.

THE ROBERT B. LIVINGSTON LECTURE

Collaborations with Bob Livingston: A Lasting Legacy

Presented with the breast committee session

Friday, April 8 | 3:30 pm PT

Featuring Daniel F. Hayes, MD | University of Michigan Rogel Cancer Center



Daniel F. Hayes, MD

Dr. Robert Boyd Livingston was a superb clinician and clinical trialist who greatly impacted the field of cancer research through a sweeping career at multiple institutions. Nationally, many of his discoveries in oncology were made through collaborative, multi-institutional efforts within SWOG Cancer Research Network, where he served as chair of the lung cancer committee (1974-1997) and the breast cancer committee (2000-2008).

In his honor and with the support of his wife Shirley, SWOG established the Dr. Robert B. Livingston Translational Breast and Lung Cancer Lectureship. The Hope Foundation for Cancer Research raises funds to support this lectureship in perpetuity and brings a special guest speaker to SWOG group meetings, alternating between a focus on lung and breast cancer advances in translational medicine.

LUNG-MAP UPDATE MEETING | FRIDAY, APRIL 6, 2:30 – 4 PM PT

A Master Protocol to Evaluate Biomarker-Driven and Immune Therapies in Previously Treated Non-Small Cell Lung Cancer

CURRENT LUNG-MAP SUB-STUDIES:

- **S1800D:** N-803 + pembrolizumab vs standard of care in patients with Stage IV or recurrent NSCLC previously treated with anti-PD-1/PD-L1 therapy
- **S1900E:** Sotorasib (AMG 510) in patients with previously treated Stage IV or recurrent KRAS G12C-mutated NSCLC

Come learn more about where the NCI's first precision medicine master protocol is and where it is going.



All welcome! | Can't attend in person? Attend virtually at bit.ly/3Mh6zut

Learn more about upcoming trials and partnership opportunities at the

SWOG CTP Update Forum

Wednesday, April 6, 11:30 am – 12:30 pm PT

SWOG CLINICAL TRIALS PARTNERSHIPS IS HOW SWOG CANCER RESEARCH NETWORK PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

swogctp.org

SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH



Friday, April 8 | 10 am – 12 pm PT

Special Symposium:
**Oncology Advanced Practice Providers
Can Enhance Clinical Research**

Hosted by the nursing research subcommittee and
the palliative and end of life care committee

Find out how to leverage the power of APPs in your setting
to expand access to clinical trials for patients.

Presentations and a panel of experts from the NCI and research bases
will include examples of best practices in both academic and community sites.
This symposium is the first component of an initiative to increase APP involvement
and will be followed by an APP-specific workshop at the fall meeting.

We hope you can join us!



THE HOPE
FOUNDATION
FOR CANCER RESEARCH

Schedule of Events

WEDNESDAY, APRIL 6, 2022

Group Meeting Registration & Information Desk
 6:30 am - 5:00 pm - Level 4 Foyer

7:00 AM – 7:20 AM

Columbia A Foyer, Level 3 CRA Clinical Trials Training Course
 Check-In

7:20 AM – 12:10 PM

Columbia A, Level 3 CRA Clinical Trials Training Course

9:00 AM – 12:00 PM

Willapa, Level 5 Advocates Committee
 (Invitation Only)

10:00 AM – 12:00 PM

306, Level 3 ORP Education Subcommittee
 (Invitation Only)

11:30 AM – 12:30 PM

402, Level 4 Clinical Trials Partnerships Update Forum

12:30 PM – 2:00 PM

307, Level 3 Core Office Staff Networking Session
 (Invitation Only)

12:00 PM – 1:45 PM

401, Level 4 Nursing Research Subcommittee
 (Invitation Only)

12:30 PM – 2:30 PM

405, Level 4 Digital Engagement Committee

1:45 PM – 4:00 PM

Columbia A, Level 3 CRA Clinical Trials Training Course
 Practicum

2:00 PM – 4:00 PM

403, Level 4 SWOG Tissue Banking Meeting
 (Invitation Only)

3:00 PM – 5:00 PM

402, Level 4

Take Action Symposium: American
 Indians, Ensuring Equity in Clinical
 Research — presented by the SWOG
 Recruitment and Retention Committee

3:30 PM – 5:00 PM

307, Level 3

Hope Foundation Board Meeting
 (Invitation Only)

4:30 PM – 5:30 PM

401, Level 4

ORP Liaison Subcommittee

4:30 PM – 6:30 PM

Quinalt, Level 5

Immunotherapeutics Committee

5:30 PM – 7:30 PM

Columbia A, Level 3

Site Operations

5:30 PM – 8:00 PM

Willapa, Level 5

NCORP Research Base Executive
 Committee Meeting (Invitation Only)

Schedule of Events

THURSDAY, APRIL 7, 2022

Group Meeting Registration & Information Desk
6:30 am - 5:00 pm - Level 4 Foyer

Hope Foundation Information Desk
8:00 am - 5:00 pm - Level 4 Foyer

Exhibits & Complimentary Coffee Service
8:00 am - 5:00 pm - Level 4 Foyer

7:00 AM – 8:00 AM

302, Level 3

NCORP/MU-NCORP Site PI Meeting

7:30 AM – 8:00 AM

Columbia B, Level 3

Jeri & Noboru Oishi Symposium Check-In

8:00 AM – 10:00 AM

307, Level 3

Quality Initiative Meeting
(Invitation Only)

8:00 AM – 11:30 AM

Columbia C, Level 3

Jeri & Noboru Oishi Symposium

8:00 AM – 10:00 AM

Quinalt, Level 5

Cancer Survivorship Committee

10:00 AM – 12:00 PM

Elwha B, Level 5

Bone Marrow & Stem Cell Transplantation
Committee

10:00 AM – 12:15 PM

Columbia D, Level 3

Early Therapeutics and Rare Cancers
Committee

10:00 AM – 12:15 PM

302, Level 3

SWOG Latin America Initiative
Symposium

10:15 AM – 12:15 PM

Quinalt, Level 5

Cancer Care Delivery Committee

12:00 PM – 1:00 PM

504, Level 5

Clinical Trials Partnerships Scientific
Advisory Board (Invitation Only)

12:00 PM – 2:00 PM

301, Level 3

Lung-MAP Site Coordinators Committee
(Invitation Only)

12:30 PM – 2:00 PM

Columbia C, Level 3

ORP Open Forum

1:00 PM – 2:00 PM

402, Level 4

S1912CD Breakout Session

1:00 PM – 2:30 PM

307, Level 3

ETxRC Committee Sarcoma Working
Group (Invitation Only)

1:00 PM – 3:00 PM

Elwha B, Level 5

Breast Working Group (Invitation Only)

1:00 PM – 3:00 PM

401, Level 4

Patient Advocacy Focus Group for
PREPARE For Your Care Activation Study
Concept (Invitation Only)

2:00 PM – 3:00 PM

302, Level 3

S2108CD Breakout Session

2:00 PM – 3:00 PM

Columbia Foyer, Level 3

Plenary Reception

3:00 PM – 4:30 PM

Columbia AB, Level 3

Plenary I (Translational Medicine)

4:30 PM – 6:30 PM

301, Level 3

Lung-MAP Administrative Meeting
(Invitation Only)

4:30 PM – 7:30 PM

Willapa, Level 5

Myeloma Working Group
(Invitation Only)

4:45 PM – 6:45 PM

302, Level 3

GI Translational Medicine Working Group
(Invitation Only)

5:00 PM – 7:00 PM

402, Level 4

Lymphoma Working Group
(Invitation Only)

5:00 PM – 7:00 PM

504, Level 5

Conflict Management Committee
(Invitation Only)

5:00 PM – 7:00 PM

Quinalt, Level 5

Palliative and End of Life Care Committee

5:00 PM – 7:00 PM

401, Level 4

Early Therapeutics Working Group
(Invitation Only)

Schedule of Events

FRIDAY, APRIL 8, 2022

Group Meeting Registration & Information Desk

6:30 am - 5:00 pm - Level 4 Foyer

Hope Foundation Information Desk

8:00 am - 5:00 pm - Level 4 Foyer

Exhibits & Complimentary Coffee Service

8:00 am - 5:00 pm - Level 4 Foyer

7:00 AM – 9:00 AM

Columbia C, Level 3

Barlogie-Salmon Myeloma Committee

7:30 AM – 8:30 AM

303, Level 3

Lung Surgical Subcommittee (Invitation Only)

7:30 AM – 9:30 AM

Columbia A, Level 3

Symptom Control and Quality of Life Committee

7:30 AM – 9:30 AM

301, Level 3

Imaging Committee (Invitation Only)

7:30 AM – 9:30 AM

307, Level 3

SWOG Data and Safety Monitoring Committee (Invitation Only)

7:30 AM – 9:30 AM

302, Level 3

Melanoma Working Group (Invitation Only)

8:00 AM – 9:30 AM

408, Level 4

Professional Review Committee (Invitation Only)

8:00 AM – 10:00 AM

401, Level 4

Breast Translational Medicine Working Group (Invitation Only)

8:00 AM – 10:00 AM

305, Level 3

Pharmaceutical Sciences Committee and Drug Information Subcommittee

8:00 AM – 12:00 PM

402, Level 4

GI Working Group (Invitation Only)

8:30 AM – 9:30 AM

303, Level 3

Lung Radiation Subcommittee (Invitation Only)

8:30 AM – 9:30 AM

407, Level 4

Lung Translational Medicine Subcommittee (Invitation Only)

9:00 AM – 11:00 AM

405, Level 4

CNS Working Group

9:00 AM – 11:00 AM

Columbia D, Level 3

Radiation Oncology: Targeting Oligometastatic Disease in GU Cancers

9:00 AM – 12:00 PM

Quinalt, Level 5

Lymphoma Committee

9:45 AM – 11:45 AM

302, Level 3

Lung Working Group (Invitation Only)

9:45 AM – 11:45 AM

Elwha B, Level 5

Prevention and Epidemiology Committee

10:00 AM – 11:30 AM

304, Level 3

Quality Assurance Committee Meeting (Invitation Only)

10:00 AM – 12:00 PM

Elwha A, Level 5

Special Symposium: Oncology Advanced Practice Providers Can Enhance Clinical Research

11:00 AM – 12:00 PM

Columbia Foyer, Level 3

Plenary Reception (Light Hors D'oeuvres)

11:30 AM – 12:00 PM

307, Level 3

Publications Committee (Invitation Only)

12:00 PM – 2:00 PM

Columbia AB, Level 3

Plenary II (General)

2:15 PM – 4:15 PM

302, Level 3

Adolescent and Young Adult (AYA) Committee

2:15 PM – 4:15 PM

402, Level 4

Surgery Committee

Schedule of Events

FRIDAY, APRIL 8, 2022

Group Meeting Registration & Information Desk
 6:30 am - 5:00 pm - Level 4 Foyer

Hope Foundation Information Desk
 8:00 am - 5:00 pm - Level 4 Foyer

Exhibits & Complimentary Coffee Service
 8:00 am - 5:00 pm - Level 4 Foyer

2:30 PM – 4:00 PM

Elwha A, Level 5 Lung-MAP Update Meeting

2:30 PM – 4:30 PM

VIRTUAL ONLY Leukemia Working Group (Invitation Only)

2:30 PM – 4:30 PM

Quinalt, Level 5 Melanoma Committee

2:45 PM – 4:45 PM

405, Level 4 VA Committee

3:00 PM – 5:00 PM

301, Level 3 ORP Executive Committee (Invitation Only)

3:00 PM – 5:00 PM

Elwha B, Level 5 GI Committee

3:15 PM – 6:15 PM

Columbia CD, Level 3 GU Committee Part I: Renal Cancer Organ Site; TM Organ Site; Cancer Control

3:30 PM – 6:30 PM

Columbia A, Level 3 Breast Committee

6:00 PM – 7:00 PM

Executive Reception (Invitation Only)

6:45 PM – 8:30 PM

Level 3 Foyer Group Reception

SATURDAY, APRIL 9, 2022

Group Meeting Registration & Information Desk
 6:30 am - 12:00 pm - Level 4 Foyer

Hope Foundation Information Desk
 8:00 am - 12:00 pm - Level 4 Foyer

7:00 AM – 7:45 AM

Elwha B, Level 5 Board of Governors (Invitation Only)

8:15 AM – 10:15 AM

VIRTUAL ONLY Leukemia Committee

8:30 AM – 11:30 AM

Columbia A, Level 3 Lung Committee

8:30 AM – 11:30 AM

Columbia CD, Level 3 GU Committee Part II: Bladder Cancer Organ Site; Prostate Cancer Organ Site

12:00 PM – 5:30 PM

402, Level 4 NCORP Strategic Retreat (Invitation Only)

12:00 PM – 2:00 PM

Elwha B, Level 5 Diversity, Equity, and Inclusion in GU Oncology in SWOG

12:00 PM – 2:00 PM

301, Level 3 Radiation Oncology Committee

Upcoming Funding Opportunities

- Virtual Grant Writing Workshop: May 1
 - NCORP Pilot Grants: June 1
 - SEED Fund Program: July 1
 - Impact Award Program: July 1
- VA Integration Support Program: August 1

See all Hope Foundation programs at

THEHOPEFOUNDATION.ORG/FUNDING-OPPORTUNITIES

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

Committees

Administrative Committees

Board of Governors

Charles D. Blanke, MD

Conflict Management

Paul Okunieff, MD

Publications

Hagen F. Kennecke, MD

Professional Review

Paul Hesketh, MD

Research Support Committees

Adolescent and Young Adult

Rebecca Johnson, MD

Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

Digital Engagement

Don S. Dizon, MD

Imaging

Lawrence H. Schwartz, MD

Immunotherapeutics

Siwen Hu-Lieskovan, MD, PhD

Katerina Politi, PhD

Oncology Research Professionals

Connie Szczepanek, RN, BSN, CCRP

Patient Advocates

Rick Bangs, MBA

Pharmaceutical Sciences

Siu-Fun Wong, PharmD

Radiation Oncology

Interim Chair

James Yu, MD

Recruitment and Retention

Allison Caban-Holt, PhD

Surgery

Syed A. Ahmad, MD

Veterans Affairs

Stephen D. Bartlett, RPh

Future Meeting Dates

2022

Fall

October 19-22

Chicago, IL

2023

Spring

April 26-29

San Francisco, CA

Fall

October 11-14

Chicago, IL

2024

Spring

April 3-6

Seattle, WA

Fall

October 16-19

Chicago, IL

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
Vice-Chair: Sikander Ailawadhi, MD
Vice-Chair: Jing Christine Ye, MD, MSc
Executive Officer: Susan M. O'Brien, MD
Statisticians: Antje Hoering, PhD
..... Rachael Sexton, MS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
Radiation: Chelsea Camille Pinnix, MD, PhD
Surgery: TBD
Imaging: Saad Z. Usmani, MD, MBA
..... Eric M. Rohren, MD, PhD
Pathology: TBD
Early Therapeutics: Frits van Rhee, MD, PhD

Designates

Digital Engagement: Saad Z. Usmani, MD, MBA
NCORP Representative: Charles S. Kuzma, MD
Veterans Affairs: Thomas R. Chauncey, MD, PhD
Data Coordinators: Sean O'Bryan
..... Hannah Hale
Oncology Research Professionals:
CRA: TBD
Nurses: Deborah A. Shaw, RN
..... Teresa Witcher, BSN, RN
Patient Advocate: Jack Aiello, MS
Pharmaceutical Science: Craig Elg, PharmD
..... Ila M. Saunders, PharmD
Protocol Project Manager: Sharon Palmer
Clinical Trials Program Manager: TBD

Time/Location

Friday, April 8, 2022 7:00 - 9:00 am
Room: Columbia C, Level 3

Agenda

Active Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19.

S2005, "A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21. Temporarily Closed: 7/16/21. Re-opened to accrual: 10/15/21.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21.

EAA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

EAA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

Closed Studies

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Santhorawala. Activated: 3/08/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Trans-plant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

Tweeting the Meeting

Twitter is a major venue you can use to get out word about what you learn at the group meeting.

@SWOG has more than 11,000 followers and can amplify your message.

Follow SWOG
at twitter.com/SWOG

With your group
meeting tweets ...

tag your @SWOG friends

use the hashtag
#SWOGonc



Barlogie-Salmon Myeloma Committee

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Le-nalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Le-nalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

Proposed Studies

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Consid-ered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ai-lawadhi, C. Ye, and A. Gowin.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Fol-lowed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Dr. P. Hagen

S1911, "Phase III Study of Optimal Induction Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM) RVd Dara +/- xx." Dr. B. Lipe.

Barlogie-Salmon Myeloma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1803 | A061202 | EAA173 | EAA181 |
|---|------------|----------|-----------|----------|
| Ascension Providence Hospitals - Southfield | 1 | 1 | - | - |
| Banner University Medical Center - Tucson | 6 | - | - | - |
| Boston Medical Center | 5 | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | 10 | - | 2 | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | 3 | - | - | - |
| Cedars-Sinai Medical Center | 5 | - | - | - |
| City of Hope Comprehensive Cancer Center | 66 | - | - | - |
| Columbus NCI Community Oncology Research Program | 7 | - | - | - |
| CommonSpirit Health Research Institute | 3 | - | - | - |
| Dayton NCI Community Oncology Research Program | 4 | - | - | - |
| Duke University - Duke Cancer Institute LAPS | 1 | - | - | - |
| Fred Hutchinson Cancer Research Center LAPS | - | - | 4 | - |
| Georgia NCI Community Oncology Research Program | 10 | - | - | - |
| Gulf South Minority Underserved NCORP | 2 | - | - | - |
| Heartland Cancer Research NCORP | 13 | - | - | - |
| Henry Ford Hospital | - | 1 | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | 31 | - | - | - |
| Lahey Hospital and Medical Center | 3 | - | - | - |
| Loyola University Medical Center | 16 | - | 2 | - |
| Medical University of South Carolina Minority Underserved NCORP | 18 | - | 1 | - |
| Moffitt Cancer Center | 30 | - | - | - |
| Montana Cancer Consortium NCORP | 3 | - | - | - |
| Nevada Cancer Research Foundation NCORP | - | - | 1 | - |
| New Mexico Minority Underserved NCORP | 6 | - | - | - |
| Ohio State University Comprehensive Cancer Center LAPS | 4 | - | - | - |
| Oregon Health and Science University | 11 | - | 2 | 2 |
| Pacific Cancer Research Consortium NCORP | 5 | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | 3 | - | - | - |
| UC Davis Comprehensive Cancer Center LAPS | 15 | - | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | 2 | - | - | - |
| University of Arkansas for Medical Sciences | - | - | - | 1 |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 18 | - | - | - |
| University of Michigan Comprehensive Cancer Center LAPS | 7 | - | - | - |
| University of Oklahoma Health Sciences Center LAPS | 1 | - | - | - |
| University of Rochester LAPS | 11 | - | - | - |
| University of Texas Health Science Center at San Antonio | 11 | - | - | - |
| University of Texas MD Anderson Cancer Center LAPS | 17 | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 10 | - | 2 | - |
| Upstate Carolina Consortium Community Oncology Research Program | 3 | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | 9 | - | - | - |
| Wisconsin NCI Community Oncology Research Program | 13 | - | - | - |
| Yale University - Yale Cancer Center LAPS | - | - | 2 | - |
| ALLIANCE | 113 | - | - | - |
| ECOG-ACRIN | 92 | - | - | - |
| NRG | 56 | - | - | - |
| Total | 644 | 2 | 16 | 3 |

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
Vice-Chair: Priyanka Sharma, MD
Executive Officer: Anne Chiang, MD, PhD
Statisticians: William E. Barlow, PhD
..... Danika Lew, MA
..... Jieling Miao, MS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
..... Andrew K. Godwin, PhD
Radiation Oncology: Reshma Jagsi, MD
Surgery: Joshua M.V. Mammen, MD, PhD
Imaging: Joanne E. Mortimer, MD
..... Wei Tse Yang, MBBS
Pathology: David L. Rimm, MD, PhD
Early Therapeutics: TBD

Designates

Cancer Control Liaisons: Melinda L. Irwin, PhD, MPH (Survivorship)
..... Dawn L. Hershman, MD (Cancer Care Delivery)
..... Banu Arun, MD (Prevention)
..... Helen K. Chew, MD (Symptom Control & QOL)
Digital Engagement: Sarah S. Mougalian, MD
NCORP Representative: Philip E. Lammers, MD
Data Coordinators: Iris Syquia
..... Larry Kaye
..... Ojasvi Mittal
..... Gabi Herbert
Oncology Research Professionals:
CRAs: Karyn N. Hart, CCRP
..... Avidanka Baftirovska, BS, CCRP
Nurse: TBD
Patient Advocates: Ginny Mason, RN, BSN
..... Roberta Albany
Pharmaceutical Science: Jorge G. Avila, PharmD
..... Dawud Nael Dawud Ellayan, PharmD
Protocol Project Manager: Alicia Aranda
Clinical Trials Program Manager: Michelle Maxim

Time/Location

Friday, April 8, 2022 3:30 - 6:30 pm
Room: Columbia A, Level 3

Agenda

3:30 – 3:35 pm Welcome and Introductions - Lajos Pusztai, M.D., D.Phil. (Chair) and Priyanka Sharma, M.D. (Vice-chair), and Alicia Aranda (SWOG Protocol Project Manager)

3:35 – 4:20 pm Robert Livingston lecture - “Collaborations with Bob Livingston: A Lasting Legacy” by Dr. Daniel F Hayes MD, FASCO, FACP

4:20 – 4:30 pm Publication update – William Barlow, Ph.D.

4:30 – 4:40 pm Patient Advocate update – Ginny Mason and Roberta Albany

4:40 – 5:00 pm Translational Medicine Sub-Committee update - Alastair Thompson, M.D. and Andrew K. Godwin, Ph.D.

5:00 – 5:40 pm Review of open CTSU trials

5:40 – 6:15 pm Recently approved and developing Concepts

6:15 – 6:25 pm Reports from Committee Liaisons

Radiotherapy - Reshma Jagsi, M.D.

Surgery – Joshua Mammen, M.D.

Cancer Survivorship - Melinda L. Irwin, Ph.D., M.P.H.

Cancer Care Delivery - Dawn Hershman, M.D.

Prevention – Banu Arun, M.D.

Symptom Control & QOL - Helen K. Chew, M.D.

NCORP (NCI Community Oncology Research Program) – Philip Lammers, M.D.

DEI - Gayathri Nagaraj, M.D.

6:30 pm Closing Comments and Adjourn

Proposed Breast Cancer Committee Studies

S2202, “Phase II Clinical Trial for Patients with Minimal Residual Disease Despite Therapy for Triple Negative Breast Cancer with Trop-2 Antibody Drug Conjugate, Sacituzumab Govitecan (DETECT-01).” Drs. Bardia, Kalinsky, Bhawe.

S2206, “Randomized Trial of Neoadjuvant Durvalumab plus Chemotherapy versus Chemotherapy alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.” Drs. Cobain and Pusztai.

S2212, “TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (TACT-II).” Dr. Sharma

Breast Committee

Active Breast Cancer Committee Studies

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi, Chalasani, Moran, Speers. Activated: 09/12/18.

S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with Recurrence Score (Rs) of 25 or Less. Rxponder: A Clinical Trial Rx Fnr Positive Node, Endocrine Responsive Breast Cancer." Drs. Kalinsky, Meric-Bernstam. Step 3 open to accrual 07/22/2021.

CTSUA/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 02/07/14.

CTSUA/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

CTSUA/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

CTSUA/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20.

CTSUA/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20.

CTSUA/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG

Champion: Dr. Jagsi. Activated: 12/24/14. Temporarily closed: 09/13/19.

CTSUA/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15.

CTSUA/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19.

CTSUA/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17. Temporarily closed: 07/02/19.

CTSUA/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

Closed Breast Cancer Committee Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai, Mammen, Henry, Jagsi. Activated: 11/15/16. Permanently closed: 06/30/21.

S1416, "Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or Without Brain Metastases." Drs. Rodler, Sharma, Hicks, and Gralow. Activated 07/07/2016. Closed: 6/16/2019.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 09/04/13. Permanently closed: 05/01/19.

S1222, "Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized

Breast Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1418 | S1706 | S2007 | A011202 | A011401 | A011502 | A011801 | B51 | EAT131 | EAT181 | EAT183 | MA39 | NRGBR003 | NRGBR004 |
|---|-------|-------|-------|---------|---------|---------|---------|-----|--------|--------|--------|------|----------|----------|
| Ascension Prov Hospitals - Southfield | 6 | 2 | - | 4 | 10 | 8 | - | 8 | 1 | 1 | - | 1 | 3 | 1 |
| Ascension Via Christi Hospitals Wichita | 9 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Banner MD Anderson CC | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | 4 | 1 | - | 1 | 6 | - | - | - | - | 2 | - | - | - | - |
| Baptist Mem HC/Mid South MU NCORP | 9 | 3 | - | 1 | 4 | - | - | - | - | - | - | - | - | 1 |
| Bay Area Tumor Inst NCORP | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Baylor U Med Ctr | - | - | - | 1 | - | - | - | 2 | - | - | - | - | - | - |
| Boston Med Ctr | - | - | - | - | 3 | - | - | - | - | 2 | - | - | - | - |
| CWRU Case CCC LAPS | 12 | - | - | - | 2 | - | - | 5 | - | - | - | 1 | 9 | 1 |
| Ca Res Consortium West Mich NCORP | 24 | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Ca Res for the Ozarks NCORP | 9 | 1 | - | - | 1 | - | 1 | - | - | - | - | - | 3 | - |
| Ca Res of Wisconsin & N Mich Consort | 7 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Carle CC NCORP | 3 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| City of Hope CCC | 9 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Columbia U MU NCORP | 8 | 1 | - | - | - | - | - | - | - | 1 | - | - | - | - |
| Columbus NCORP | 13 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | 19 | 1 | - | - | 2 | - | - | 2 | - | - | - | - | - | - |
| Cotton O'Neil CC / Stormont Vail Hlth | - | - | - | 1 | 1 | - | - | - | - | - | - | - | 1 | - |
| Dayton NCORP | 3 | - | - | - | 1 | - | - | - | 1 | 2 | - | - | - | - |
| Desert Regional Med Ctr | 1 | - | - | 7 | 4 | - | - | 4 | - | - | - | - | - | - |
| Essentia Health NCORP | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | 10 | 2 | - | - | 12 | 9 | - | - | - | - | - | - | - | - |
| Georgia NCORP | 23 | 2 | - | - | 2 | 1 | - | - | 4 | - | - | - | 1 | - |
| Gulf South MU NCORP | 5 | 1 | - | - | - | - | - | - | - | 2 | - | - | 4 | - |
| Hawaii MU NCORP | 5 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Heartland Ca Res NCORP | 19 | 3 | - | - | - | 1 | - | - | - | - | - | - | - | - |
| Henry Ford Hospital | 1 | - | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Houston Methodist Hospital | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - | - |
| Kaiser Permanente NCORP | 51 | - | - | 1 | 55 | 25 | - | - | - | - | - | - | 25 | 1 |
| Lahey Hospital & Med Ctr | 3 | - | - | - | 9 | 5 | - | - | 1 | 4 | - | - | - | 1 |
| Loma Linda U Med Ctr | 1 | - | - | 3 | - | - | - | 3 | - | - | - | - | - | - |
| Loyola U Med Ctr | 3 | - | - | - | 6 | 7 | - | 1 | 2 | 1 | - | - | - | - |
| Massachusetts Veterans ERIC | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - |
| Medical U South Carolina MU NCORP | 11 | - | - | - | - | - | - | - | - | - | 3 | - | - | - |
| Meharry Medical College | - | - | - | - | 3 | - | - | - | - | - | - | - | 1 | - |
| Michigan Ca Res Consortium NCORP | 21 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Moffitt CC | - | - | - | 1 | 3 | 2 | - | - | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | 2 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| Mount Sinai Hospital | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | 4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Nevada Ca Res Foundation NCORP | 11 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| New Mexico MU NCORP | 19 | 4 | - | - | - | - | - | - | - | - | - | - | - | - |

Breast Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1418 | S1706 | S2007 | A011202 | A011401 | A011502 | A011801 | B51 | EA1731 | EA1781 | EA1783 | MA39 | NRGBR003 | NRGBR004 |
|---------------------------------------|--------------|-----------|----------|------------|------------|------------|----------|-----------|-----------|-----------|----------|----------|-----------|----------|
| Northwell Health NCORP | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Northwestern U LAPS | 2 | 1 | - | - | - | - | - | - | - | 2 | 1 | - | 1 | - |
| Ohio State U CCC LAPS | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Oregon Health & Science U | 19 | - | - | - | - | - | - | 1 | - | - | 3 | - | 3 | - |
| Orlando Health Ca Inst | 1 | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Pacific Ca Res Consortium NCORP | 19 | - | - | - | 3 | 1 | - | - | - | - | - | - | 1 | - |
| SCL Health Saint Joseph Hospital | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Salem Hospital | - | - | - | 4 | - | - | - | - | - | - | - | - | - | - |
| Scott & White Mem Hospital | - | - | - | - | 4 | - | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | 46 | - | - | - | - | 6 | - | - | - | - | - | - | - | - |
| Sutter Ca Res Consortium | 3 | - | - | - | 8 | 2 | 2 | 2 | 1 | 3 | - | - | 4 | 2 |
| Don & Sybil Harrington CC | 7 | 3 | - | 11 | 8 | - | 1 | 1 | - | - | - | - | - | - |
| James Graham Brown CC at U Louisville | - | - | - | 2 | - | - | - | - | - | - | - | - | - | - |
| West Clinic - Wolf River | - | - | - | 9 | - | - | - | 4 | - | - | - | - | - | - |
| UC Davis CCC LAPS | 8 | 4 | - | 2 | 4 | 17 | - | - | - | - | - | - | - | - |
| UC Irvine Health/Chao Family CCC | 6 | - | - | 3 | 2 | 2 | - | 1 | - | - | - | - | 1 | - |
| UC San Diego Moores CC | - | - | - | - | 2 | 3 | - | - | - | - | - | - | 1 | - |
| USC Norris CCC LAPS | 3 | - | - | 4 | - | 6 | - | - | - | - | - | 2 | - | - |
| U Arkansas for Medical Sciences | 17 | 2 | - | - | 3 | 22 | - | - | - | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - |
| U Colorado CC LAPS | 11 | 1 | - | 42 | 27 | 7 | 1 | 3 | - | 10 | - | - | - | - |
| U Kansas CC - MCA Rural MU NCORP | 22 | 2 | - | 4 | 23 | 9 | - | - | - | - | - | - | - | - |
| U Kentucky/Markey CC | - | - | - | - | - | 3 | - | 1 | - | - | - | - | - | - |
| U Michigan CCC LAPS | 13 | 2 | - | - | 14 | 11 | - | - | - | 1 | - | 4 | 3 | - |
| U Mississippi Med Ctr | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - |
| U Oklahoma Health Sciences Ctr LAPS | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| U Rochester LAPS | 2 | 1 | - | - | - | 15 | - | - | 7 | 1 | - | - | 9 | - |
| U Texas HSC at San Antonio | 5 | - | 1 | 6 | 2 | 1 | - | 5 | - | - | - | - | 4 | - |
| U Texas MD Anderson CC LAPS | 21 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| U Utah - Huntsman Ca Inst LAPS | 6 | 2 | - | - | 7 | - | 1 | - | - | 2 | - | - | - | - |
| Upstate Carolina Consortium NCORP | 8 | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Virginia Mason Med Ctr | 1 | - | - | - | - | - | - | 1 | - | - | - | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | 3 | - | - | 11 | 12 | 9 | - | - | 6 | 9 | 2 | - | 6 | - |
| Western States Ca Res NCORP | 4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| William Beaumont Hosp-Royal Oak | 1 | - | - | 6 | 5 | 2 | - | 1 | - | - | - | - | - | - |
| Wisconsin NCORP | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | 8 | - | - | 5 | 81 | 31 | - | - | 6 | 1 | - | - | 9 | - |
| ALLIANCE | 144 | 10 | - | - | - | - | - | - | - | - | - | - | - | - |
| CCTG | 39 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | 129 | 5 | 1 | - | - | - | - | - | - | - | - | - | - | - |
| NRG | 307 | 33 | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | 1,195 | 97 | 4 | 129 | 333 | 206 | 7 | 47 | 30 | 45 | 9 | 8 | 89 | 7 |

Breast Committee

Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor-Positive Stage IV Breast Cancer." Drs. Moore, Somlo, Hayes, Kuhn, and Hicks. Activated 05/09/2014. Permanently Closed 10/15/2015.

Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd, Leja, Fabian, Godwin. Activated: 09/15/17.

Active Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, Feld. Activated: 02/21/19.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, Hertz. Activated 03/01/19.

Active Cancer Care Delivery Studies

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino, Hershman, Ramsey. Activated: 07/16/18.

Active Cancer Prevention Studies

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, Thomas, Caban-Holt. Activated: 09/01/20.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17.

Active Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel, Chae, Kurzrock. Activated 01/13/17.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15.

Cancer Control & Prevention Committee

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Cancer Survivorship Co-Chairs: Halle C.F. Moore, MD
 Melinda L. Irwin, PhD, MPH
 Palliative & End of Life Co-Chairs: Robert S. Krouse, MD, FACS
 Mark A. O'Rourke, MD
 Marie Bakitas, DNSc, CRNP
 Prevention and Epidemiology Co-Chairs: Banu Arun, MD
 Marian L. Neuhaus, PhD, RD
 Symptom Control & QOL Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (Palliative, Prevention,
 Survivorship)
 Gary H. Lyman, MD (CCD, Symptom Control & QOL)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Garnet Anderson, PhD
 William E. Barlow, PhD
 Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Riha Vaidya, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Phyllis J. Goodman, MS
 Danika Lew, MA
 Hongli Li, MS
 Anna Moseley, MS
 Eddie Mayerson, MS
 Administrative Lead SDMC: Monica Yee, CCRP
 Scientific Leadership
 NCORP Representative: Mark A. O'Rourke, MD
 Radiation Oncology Committee: Louis "Sandy" Constine, MD
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Melinda L. Irwin, PhD, MPH (Survivorship)
 Helen K. Chew, MD (Symptom Control & QOL)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD

Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Peter J. Van Veldhuizen, Jr., MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment and Retention Committee: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Control & QOL)
 Veterans Affairs: Yeun-Hee Anna Park, MD
 Designates
 Clinical Research Associates: Amanda R. Dinsdale, MHA, CCRC
 Samantha Wright, MS, CCRP
 Nurses: Connie Szczepanek, RN, BSN
 Melyssa W. Foust, MSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 SDMC Data Coordinators and Staff: Kimberly Carvalho
 Sam Dzingle
 Diane Liggett, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, CCRP
 Recruitment and Retention Specialist: TBD
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Amy Geschwender, PhD (Symptom Control & QOL)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention & Epidemiology)
 Valerie Fraser (Palliative & End of Life Care)
 Desiree Walker, BA (Recruitment & Retention)
 Protocol Project Manager (CCD; Prevention): Patricia O'Kane
 Protocol Project Manager (Survivorship): Taj Pereira
 Protocol Project Manager (Symptom Control): Mariah Norman, MS
 Protocol Project Manager (Palliative Care): Christy Klepetko
 Clinical Trials Program Manager (Palliative Care): Michelle Maxim
 Clinical Trials Program Manager (CCD; Prevention; Survivorship): TBD
 Clinical Trials Project Manager (Symptom Control): Crystal Miwa

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Dawn L. Hershman, MD, MS
..... Scott D. Ramsey, MD, PhD

Time/Location

Thursday, April 7, 2022 10:15 am - 12:15 pm
Room: Quinalt, Level 5

Agenda

Presentations

Using Implementation Science to Facilitate Deprescribing for Multimorbid Adults with Cancer, Cara McDermott, PharmD, PhD, Fred Hutchinson Cancer Research Institute

Recruiting Patient/Caregiver Dyads - Strategies and Challenges and Panel Discussion, Veena Shankaran, University of Washington; Christine Veenstra, M.D., University of Michigan; Daniela Wittman, University of Michigan; Lee Jones, SWOG Patient Advocate

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran, University of Washington. Activated 7/26/21.

Development of a Dyadic Module to Promote Guideline-Concordant Colorectal Cancer Surveillance – Christine Veenstra, M.D., University of Michigan

Approved Protocol

S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Jens Rueter, M.D., Maine Cancer Genomics Initiative; Meghna Trivedi, M.D., Columbia University

Active Studies

S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer," Dr. M. Accordini. Activated 7/16/18.

Mednet Update - Elizabeth Henry, theMednet

Developing Studies

S2201CD, Managing Oral Anti-Cancer Agents in Community Oncology Practices: Implementation and Impact, Karen B. Farris, Ph.D., Emily Mackler, Pharm.D., University of Michigan

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, MD, MBA, Izumi Okado, PhD, University of Hawaii

Studies with CCD/CCP Components

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)," Dr. K. Crew. Activated 9/1/20. (Committee: Prevention/Epidemiology)

S2010, Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast Cancer – Lynn Henry, M.D., University of Michigan; Dawn Hershman, M.S. M.S., Columbia University

Closed Studies

S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

Database/Grant Funded Projects

Ongoing

Trends in Obesity Among Patients Registered to SWOG Cancer Clinical Treatment Trials. Riha Vaidya, Ph.D.

Cancer Care Delivery (CCD) Committee

Published

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/ Immunotherapy and Targeted Agent Cancer Clinical Trials. Joseph Unger, Ph.D.

Active and Completed CCDR Studies from Other Research Bases

A231601CD*** - Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

A231701CD (closed to accrual)* - Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

A231901CD* - Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

A191402CD (completed)* - Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

A231602CD (completed)** - Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma

COG-ACCL15N1CD (completed)*** - Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

COG-ACCL16N1CD (closed to accrual)*** - Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

EAQ171CD* - Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

EAQ161CD (completed)*** - Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

EAQ162CD (completed)*** - Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

NRG-CC007CD*** - Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy

S1415CD (completed)** - A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)

S1417CD (completed)** - S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

S1912CD* - A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

S2108CD*** - Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care

WF-20817CD (completed)* - Implementation of Smoking Cessation Within NCI NCORP Community Sites

WF-1803CD (completed)*** - Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices

WF-30917CD (completed)* - Stepped-Care Telehealth for Distress in Cancer Survivors

WF-1804CD* - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

WF-1805CD** - Implementation and Effectiveness Trial of HN-STAR

URCC-18110CD* - Learning Collaborative Vs Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers

URCC-18004CD*** - Understanding the Impact of Drug Shortages on Oncology Care Delivery

* Studies funded by federal agencies and reviewed at CSR

** Studies funded by non-federal agencies and reviewed by Steering Committee

***Studies funded by NCORP and reviewed by Steering Committee

Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1703 | S1912CD | S1916 | A191901 | A231601C | A231602C | A231701C | EAQ171CD | EAQ202 | NHLBIMDS | NRGCC07 |
|---------------------------------------|------------|----------|----------|-----------|----------|----------|----------|----------|----------|------------|-----------|
| Ascension Prov Hospitals - Southfield | - | - | - | 2 | - | - | - | - | - | 1 | - |
| Banner U Med Ctr - Tucson | 1 | - | - | - | - | - | - | - | - | - | - |
| CWRU Case CCC LAPS | 12 | - | - | - | - | - | - | - | - | 5 | - |
| Ca Res for the Ozarks NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| Ca Res of Wisconsin & N Mich Consort | 8 | - | - | 1 | - | - | - | - | - | - | - |
| Carle CC NCORP | 7 | - | 1 | - | - | - | - | - | - | - | - |
| Columbia U MU NCORP | 14 | 1 | - | - | - | - | - | - | - | 12 | - |
| Columbus NCORP | 3 | - | - | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | 7 | - | - | - | - | - | - | - | - | - | - |
| Cotton O'Neil CC / Stormont Vail Hlth | 1 | - | - | - | - | - | - | - | - | - | - |
| Dayton NCORP | 3 | - | - | - | - | - | - | - | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | - | - | - | - | - | - | - | - | - | 15 | - |
| Georgia NCORP | 1 | - | - | - | - | - | - | - | - | - | - |
| Gulf South MU NCORP | 6 | - | - | - | 1 | - | - | - | - | - | - |
| Hawaii MU NCORP | 4 | - | - | - | - | - | - | - | - | 5 | - |
| Heartland Ca Res NCORP | 10 | 2 | 1 | - | - | - | - | - | - | - | 1 |
| Kaiser Permanente NCORP | 4 | - | - | - | - | - | - | - | - | 5 | - |
| Kansas City Veterans Affairs Med Ctr | - | - | - | - | - | - | - | - | - | 4 | - |
| Kansas Inst of Med Cancer & Blood Ctr | - | - | - | - | - | - | - | - | - | 2 | - |
| Lahey Hospital & Med Ctr | 4 | - | - | - | - | - | - | - | - | - | - |
| Loyola U Med Ctr | 2 | - | - | 3 | - | - | - | - | - | - | - |
| Massachusetts Veterans ERIC | - | - | - | - | - | - | - | - | - | 26 | - |
| Medical U South Carolina MU NCORP | - | - | - | - | - | - | 1 | - | - | 2 | - |
| Michigan Ca Res Consortium NCORP | 7 | - | - | - | - | - | - | - | - | - | - |
| Moffitt CC | - | - | - | - | - | - | - | - | - | 8 | - |
| Montana Cancer Consortium NCORP | 7 | - | - | - | - | - | - | - | - | - | - |
| MultiCare Tacoma General Hospital | - | - | - | 13 | - | - | - | 1 | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | 6 | - | - | - | - | - | - | - | 6 | 2 | - |
| Nevada Ca Res Foundation NCORP | 1 | - | - | - | - | - | - | - | - | - | - |
| New Mexico MU NCORP | 9 | - | - | - | - | - | - | - | - | - | - |
| Oregon Health & Science U | - | - | - | - | - | - | - | - | - | 6 | - |
| Pacific Ca Res Consortium NCORP | 9 | 1 | - | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | 4 | - | - | - | - | - | - | - | - | - | - |
| UC Irvine Health/Chao Family CCC | - | - | - | - | - | - | - | - | - | 18 | - |
| UC San Diego Moores CC | - | - | - | - | - | - | - | - | - | 21 | - |
| U Arkansas for Medical Sciences | 3 | - | - | - | - | - | - | - | - | - | - |
| U Colorado CC LAPS | - | - | - | - | - | - | - | - | - | 6 | - |
| U Kansas CC - MCA Rural MU NCORP | 5 | 1 | - | - | - | 4 | - | - | - | - | 21 |
| U Rochester LAPS | 4 | - | - | - | - | - | - | - | - | - | - |
| Western States Ca Res NCORP | - | - | - | 1 | - | - | - | - | - | - | - |
| William Beaumont Hosp-Royal Oak | - | - | - | - | - | - | - | - | - | 2 | - |
| Wisconsin NCORP | 1 | - | - | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | 25 | - | - | - | - | - | - | - | - | 7 | - |
| ALLIANCE | 4 | - | - | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | 16 | - | - | - | - | - | - | - | - | - | - |
| NRG | 12 | - | - | - | - | - | - | - | - | - | - |
| Total | 200 | 6 | 2 | 20 | 1 | 4 | 1 | 1 | 6 | 147 | 22 |

Cancer Survivorship Committee

Leadership

Co-Chairs Melinda Irwin, PhD, MPH
..... Halle Moore, MD

Time/Location

Thursday, April 7, 2022 8:00 - 10:00 am
Room: Quinalt, Level 5

Agenda

Welcome: Melinda Irwin and Halle Moore

Survivorship Presentation: NCI Cancer Survivorship Priorities - Emily Tonorezos, MD MPH Director, Office of Cancer Survivorship Division of Cancer Control and Population Sciences, National Cancer Institute.

Discussion

Patient Advocate Update: Lee Jones

New Ideas

Studies/Concepts:

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer." Justin Floyd, D.O. and Monika Leja, M.D.

S2204, "Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers." Dan Raz and Virginia Sun.

S2013 I-CHECKIT: Immune CHECKpoint Inhibitory Toxicity analysis: Krishna Gunturu; Concept approved (Also in QOL and Symptom Control Committee)

Impact of immune checkpoint inhibitors on gonadal reserve: a longitudinal analysis of biospecimens from S1404: Katy Tsai

SWOG 0816 a secondary analysis of predictors of muscle wasting, Vickie Baracos

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization: Christine Duffy

Obesity, metabolomics, microbiome and cancer outcomes: Leah Ferrucci

ALTE2131: "Gonadotropin-Releasing Hormone Analogs (GnRHa) and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer." COG led, SWOG champion is Halle Moore

Use of Continuous Glucose Monitoring to Improve Glycemic Safety and Reduce Infectious Complications in AYA ALL patients: GOG led (Allison Grimes), SWOG champion is Stephanie Tsai

Liaison Updates

Cardiac Advisory Panel Update

Other Business

Active Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. J. Floyd and M. Leja. Activated 9/15/2017.

Concepts in Development

S2204, "Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers." Drs. D. Raz and V. Sun.

Closed Study

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. R. Krouse, J. Denevee, and V. Sun. Activated: 3/9/15; Permanently Closed: 5/15/20.

Cancer Survivorship Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1501 | E1011 | EA9131 |
|--|------------|-----------|-----------|
| <i>Ascension Providence Hospitals - Southfield</i> | 4 | - | - |
| <i>Baptist Memorial Health Care/Mid South Minority Underserved NCORP</i> | 6 | - | 1 |
| <i>Bay Area Tumor Institute NCORP</i> | 2 | - | - |
| <i>CWRU Case Comprehensive Cancer Center LAPS</i> | 14 | - | - |
| <i>Cancer Research for the Ozarks NCORP</i> | 9 | - | - |
| <i>City of Hope Comprehensive Cancer Center</i> | 43 | - | - |
| <i>Columbia University Minority Underserved NCORP</i> | 2 | - | - |
| <i>CommonSpirit Health Research Institute</i> | 1 | - | - |
| <i>Fred Hutchinson Cancer Research Center LAPS</i> | 3 | - | - |
| <i>Georgia Cares Minority Underserved NCORP</i> | - | - | 1 |
| <i>Georgia NCI Community Oncology Research Program</i> | 11 | - | - |
| <i>Gulf South Minority Underserved NCORP</i> | 4 | - | - |
| <i>Hawaii Minority Underserved NCORP</i> | - | 21 | - |
| <i>Heartland Cancer Research NCORP</i> | 18 | - | - |
| <i>Henry Ford Hospital</i> | 1 | - | - |
| <i>Kaiser Permanente NCI Community Oncology Research Program</i> | 1 | - | 60 |
| <i>King Faisal Specialist Hospital and Research Centre</i> | 3 | - | - |
| <i>Lahey Hospital and Medical Center</i> | 6 | - | - |
| <i>Loyola University Medical Center</i> | 8 | - | - |
| <i>Medical University of South Carolina Minority Underserved NCORP</i> | 1 | - | - |
| <i>Michigan Cancer Research Consortium NCORP</i> | 3 | - | - |
| <i>Moffitt Cancer Center</i> | 13 | - | - |
| <i>Montana Cancer Consortium NCORP</i> | 1 | - | - |
| <i>NCORP of the Carolinas (Prisma Health NCORP)</i> | 2 | - | - |
| <i>New Mexico Minority Underserved NCORP</i> | 5 | 1 | - |
| <i>Oregon Health and Science University</i> | 1 | - | - |
| <i>UC Davis Comprehensive Cancer Center LAPS</i> | 2 | - | - |
| <i>USC Norris Comprehensive Cancer Center LAPS</i> | 4 | - | - |
| <i>University of Kansas Cancer Center - MCA Rural MU NCORP</i> | 6 | - | - |
| <i>University of Michigan Comprehensive Cancer Center LAPS</i> | 9 | - | - |
| <i>Upstate Carolina Consortium Community Oncology Research Program</i> | - | 1 | - |
| <i>Wayne State University - Karmanos Cancer Institute LAPS</i> | 6 | - | - |
| ALLIANCE | 19 | - | - |
| ECOG-ACRIN | 32 | - | - |
| NRG | 20 | - | - |
| Total | 260 | 23 | 62 |

Palliative and End of Life Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Mark A. O'Rourke, MD
 Marie Bakitas, DNSc

Time/Location

Thursday, April 7, 2022 5:00 - 7:00 pm
 Room: Quinalt, Level 5

Agenda

- 5 minutes Welcome and Introductions – Co-Chairs
- 5 minutes Committee Liaison Updates (Patient Advocates/ORP)
- 10 minutes Committee Member Wellbeing Check-in / Marie A. Bakitas, DNSc, NP-C, FAAN
- 25 minutes Plenary: "Redefining Professional Wellness for the Oncology Workforce" Ishwaria Subbiah, MD, MS
- 15 minutes Developing Studies Updates
 - S2016**, "Randomized Phase III Trial of a Primary Palliative Care Intervention in Pancreatic Cancer." Drs. Chung and Sun.
 - S2106**, "Depression Screening and Treatment in Patients Requesting Medical Aid in Dying (MAID)" Drs. Salman and Blanke.
- 10 minutes Active Study Updates
 - S1820**, "A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)." Dr. Sun. Activated: 12/9/19.
 - Hope/CAPC Provider Communication Study: Subbiah/Agarwal
- 5 minutes Closed Study Update
 - S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15; Closed: 5/15/20.
- 35 minutes New Business
 1. Hope Intervention Workshop for Metastatic Breast Ca Proposal: Corn/Feldman
 2. PREPARE for Your Care: An outpatient advanced care planning intervention for older adults with advanced cancer (PCRC Submission) Myers/O'Rourke/Bakitas

Palliative and End of Life Care Committee

**Accrual from trial opening through 12/31/2021
 by Institution and Study**

| | S1820 |
|---|-----------|
| Banner University Medical Center - Tucson | 1 |
| City of Hope Comprehensive Cancer Center | 2 |
| Columbus NCI Community Oncology Research Program | 1 |
| Fred Hutchinson Cancer Research Center LAPS | 6 |
| Hawaii Minority Underserved NCORP | 2 |
| Heartland Cancer Research NCORP | 7 |
| Michigan Cancer Research Consortium NCORP | 2 |
| NCORP of the Carolinas (Prisma Health NCORP) | 5 |
| New Mexico Minority Underserved NCORP | 2 |
| Northwestern University LAPS | 2 |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | 10 |
| University of Texas MD Anderson Cancer Center LAPS | 7 |
| Upstate Carolina Consortium Community Oncology Research Program | 2 |
| Virginia Mason Medical Center | 5 |
| ALLIANCE | 4 |
| ECOG-ACRIN | 1 |
| NRG | 20 |
| Total | 79 |

3. READIBAND Activity Monitor Concept: Fowler/O'Rourke
 4. "Randomized multicenter placebo-controlled trial evaluating lanreotide for the reduction of postoperative pancreatic fistulae"- Jonathan G. Sham, MD submission for Charles A. Coltman, Jr. Fellowship Program
 5. APP workshop f/u
- 5 Minutes Closing Comments and Adjourn: Co-Chairs

Palliative and End of Life Care Committee

Active Studies

S1820, "A Randomized Phase II Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors (AIMS-RC)." Dr. Sun. Activated: 12/9/19.

Proposed Studies

S2016, "Randomized Phase III Trial of a Primary Palliative Care Intervention in Pancreatic Cancer." Drs. Chung and Sun.

S2106, "Depression screening and treatment in patients requesting Medical Aid in Dying (MAID)." Drs. Salman and Blanke.

Closed Studies

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15. Permanently Closed: 5/15/20.

Find Clinical Research Resources on the SWOG Website

SWOG launched a clinical research clearinghouse that features a wide range of curated resources that are relevant to conducting clinical trials (from idea inception, to design, logistics, funding, data analysis, and publication), as well as specific information related to conducting research within the cooperative group network.

The goal is simple: provide a one-stop shop for educational and professional development resources for our members and staff!



Check it out at [swog.org/clinical-research-resources](https://www.swog.org/clinical-research-resources)

Prevention & Epidemiology Committee

Leadership

Co-Chairs: Banu Arun, MD
..... Marian L. Neuhouser, PhD, RD

Time/Location

Friday, April 8, 2022 9:45 - 11:45 am

Room: Elwha B, Level 5

Agenda

Welcome and Opening Comments: Marian Neuhouser and Banu Arun

Cancer Prevention Presentation:

"Biomarker development for early phase clinical trials for melanoma prevention" Presented by Dr. Karen Taraszka Hastings, Associate Professor, University of AZ

Active Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

CTSU/NHLBI-MDS, "The National Myelodysplastic Syndromes Natural History Study." Drs. D. Hill and C. Arana Yi, Study Champions. SWOG Activated: 6/1/19.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun, Study Champion. SWOG Activated: 7/24/19.

CTSU A151804, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 6/15/20.

CTSU A212102, "A Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. SWOG Activation: TBD.

Pending CTEP Approval

Amendment to S1418, "Exploratory Study to Evaluate Mammographic Density Changes in Patients Receiving Pembrolizumab in S1418." Dr. B. Arun.

Amendment to S1007, "Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007." Drs. K. Crew, K. Kalinsky, R. Ha.

Concepts in Redesign

"Phase II Study of Intraoperative Radiotherapy (IORT) for DCIS after Breast Conserving Surgery." Dr. E. Connolly.

"Alternate Dosing of Exemestane Among Postmenopausal Women with Atypical Hyperplasia or Ductal Carcinoma In Situ", Dr. Julia McGuinness.

Patient Advocate update: Cheryl Jernigan

New Business/Open Discussion for new ideas

Prevention & Epidemiology Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S0820 | S1823 | S1904 | A211102 | A211601 | EA1151 | EA2185 | NRGCC008 |
|---|-------|-------|-------|---------|---------|--------|--------|----------|
| Ascension Providence Hospitals - Southfield | 1 | - | - | - | 2 | - | - | - |
| Ascension Via Christi Hospitals Wichita | 12 | - | - | - | - | - | - | - |
| Banner MD Anderson Cancer Center | 10 | - | - | - | - | 1 | - | - |
| Banner University Medical Center - Tucson | - | 3 | - | - | - | 56 | - | - |
| Baptist Memorial Health Care/Mid South Minority Underserved NCORP | 4 | - | 2 | - | - | - | - | - |
| Bay Area Tumor Institute NCORP | 1 | 4 | - | - | - | - | - | - |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | - | - | - | - | - | - | - | 1 |
| Brooke Army Medical Center | 1 | - | - | - | - | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - | - | 83 | - | - |
| Cancer Research Consortium of West Michigan NCORP | 2 | - | - | - | - | - | - | - |
| Cancer Research for the Ozarks NCORP | - | 5 | - | - | - | - | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | 1 | - | - | - | - | - | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | 4 | 10 | - | - | - | - | - |
| City of Hope Comprehensive Cancer Center | 1 | - | 7 | 2 | - | - | - | - |
| Columbia University Minority Underserved NCORP | 1 | - | 17 | 1 | - | - | - | - |
| Columbus NCI Community Oncology Research Program | 6 | 7 | - | - | - | - | - | - |
| CommonSpirit Health Research Institute | 4 | - | - | - | - | - | - | - |
| Dayton NCI Community Oncology Research Program | 1 | - | - | - | - | - | - | - |
| Essentia Health NCI Community Oncology Research Program | 4 | 1 | - | - | - | 77 | - | - |
| Georgia Cares Minority Underserved NCORP | 2 | - | - | - | - | - | - | - |
| Georgia NCI Community Oncology Research Program | 2 | - | - | - | - | - | - | - |
| Gulf South Minority Underserved NCORP | - | 6 | - | - | - | - | - | - |
| Hawaii Minority Underserved NCORP | 10 | 2 | 2 | - | - | - | - | - |
| Heartland Cancer Research NCORP | 2 | 12 | 2 | - | - | - | - | - |
| Henry Ford Hospital | - | - | - | - | - | 129 | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | 40 | 68 | - | - | - | - | - | - |
| Lahey Hospital and Medical Center | - | - | 3 | - | - | - | - | - |
| Loma Linda University Medical Center | 2 | 2 | - | - | - | - | - | - |
| Loyola University Medical Center | 2 | - | - | - | - | - | - | - |
| Massachusetts Veterans Epidemiology Research and Information Center | 3 | - | - | - | - | - | 5 | - |
| Medical University of South Carolina Minority Underserved NCORP | - | - | - | - | - | 4 | - | - |
| Meharry Medical College | 1 | - | - | - | - | - | - | - |
| Memorial Hermann Texas Medical Center | - | - | - | - | - | 8 | - | - |
| Michigan Cancer Research Consortium NCORP | 11 | - | - | - | - | - | - | - |
| MultiCare Tacoma General Hospital | 2 | - | - | - | - | - | - | - |

Prevention & Epidemiology Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S0820 | S1823 | S1904 | A211102 | A211601 | EA1151 | EA2185 | NRGCC008 |
|---|------------|------------|------------|----------|----------|--------------|----------|----------|
| NCORP of the Carolinas (Prisma Health NCORP) | - | 7 | - | - | - | 313 | - | - |
| Nevada Cancer Research Foundation NCORP | 1 | 1 | - | - | - | - | - | - |
| New Mexico Minority Underserved NCORP | 2 | 3 | - | - | - | - | - | - |
| Northwell Health NCORP | - | 6 | - | - | - | - | - | - |
| Ohio State University Comprehensive Cancer Center LAPS | - | 1 | - | - | - | - | - | - |
| Oregon Health and Science University | - | 9 | - | - | - | - | - | - |
| Pacific Cancer Research Consortium NCORP | 2 | - | - | - | - | - | - | - |
| Salem Hospital | - | 2 | - | - | - | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | 3 | 2 | - | - | - | - | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | 29 | 2 | - | - | - | - | - | - |
| UC San Diego Moores Cancer Center | - | 16 | - | - | - | - | - | - |
| UCLA / Jonsson Comprehensive Cancer Center | - | 24 | - | - | - | - | - | - |
| USC Norris Comprehensive Cancer Center LAPS | 5 | 24 | - | - | - | - | - | - |
| University of Arkansas for Medical Sciences | - | - | - | - | - | 314 | - | - |
| University of Cincinnati Cancer Center-UC Medical Center | - | 2 | - | - | - | - | - | - |
| University of Colorado Cancer Center LAPS | 7 | 6 | - | - | - | 2 | - | - |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 4 | - | - | - | - | - | - | - |
| University of Kentucky/Markey Cancer Center | - | - | - | - | - | 8 | - | - |
| University of Mississippi Medical Center | 1 | 3 | - | - | - | - | - | - |
| University of Oklahoma Health Sciences Center LAPS | - | 1 | - | - | - | - | - | - |
| University of Rochester LAPS | - | 9 | - | - | - | 223 | - | - |
| University of Texas Health Science Center at San Antonio | 9 | - | - | - | - | - | - | - |
| University of Texas MD Anderson Cancer Center LAPS | 4 | - | - | - | - | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | - | - | 15 | - | - | - | - | - |
| Upstate Carolina Consortium Community Oncology Research Program | - | - | - | - | - | 619 | - | - |
| Vanderbilt University - Ingram Cancer Center LAPS | - | 6 | - | - | - | - | - | - |
| Virginia Mason Medical Center | 9 | 8 | - | - | - | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | 2 | - | - | - | - | - | - | - |
| Western States Cancer Research NCORP | 1 | - | - | - | - | 57 | - | - |
| Wisconsin NCI Community Oncology Research Program | 1 | - | - | - | - | - | - | - |
| Yale University - Yale Cancer Center LAPS | 23 | - | - | - | - | - | - | - |
| ALLIANCE | 34 | 47 | 20 | - | - | - | - | - |
| CCTG | - | 57 | - | - | - | - | - | - |
| ECOG-ACRIN | 26 | 26 | 6 | - | - | - | - | - |
| NRG | 37 | 13 | 23 | - | - | - | - | - |
| Total | 326 | 389 | 107 | 3 | 2 | 1,894 | 5 | 1 |

Symptom Control & Quality of Life Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
..... Norah Lynn Henry, MD, PhD

Time/Location

Friday, April 8, 2022 7:30 - 9:30 am
Room: Columbia A, Level 3

Agenda

Symposium: Patient-Reported Outcomes and Toxicity Evaluation

Plenary speaker: Gita Thanarajasingam, MD

Panel discussion

Active Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating The Effect Of Immune-Enhancing Nutrition On Radical Cystectomy Outcomes" - Dr.Hamilton-Reeves. Activated 2/21/19.

S1614, "A Phase III Randomized Trial Of Prophylactic Antiviral Therapy In Patients With Current Or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy For Solid Tumors." Drs. Hwang, Lok, and Ghering, et al. Activated 2/21/19, re-activated 7/1/21.

S2013, "Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective Observational Study" – Drs. Gunturu, Hershman, and Kuderer. Activated 8/16/21

Other Concepts in Development

S2205, "STOP CIPN: Randomized trial of Limb Cryocompression versus Continuous Compression versus Low Cyclic Compression for the Prevention of Taxane-Induced peripheral Neuropathy." Dr. Accordini

S2010, "Improving Endocrine Therapy Persistence in Young Women with Breast Cancer using Active Symptom Monitoring." Dr. Henry

Closed Studies

S1714, "A Prospective Observational Cohort Study To Develop A Predictive Model Of Taxane-Induced Peripheral Neuropathy In Cancer Patients"- Drs. Trivedi, Hershman, Brannagan, et al. Activated 3/1/19.

S0702, "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak and Dr. Gralow M.D. Activated 12/15/2008. Closed to Accrual 06/01/19.

S1200, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 3/27/12. Closed: 2/15/17.

Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What has SCQOL contributed to the literature recently?
4. What other updates should we know about

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordini, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

Symptom Control & Quality of Life Committee

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Palliative Care and End of Life

S1820, "A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)." Drs. Sun, Thomson, Crane, et al. Activated: 12/9/20.

Prevention and Epidemiology

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices On Incorporating Chemoprevention Into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

NCTN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1600 | S1614 | S1714 | S2013 | A221505 |
|---|------------|----------|--------------|-----------|-----------|
| Ascension Providence Hospitals - Southfield | - | - | - | 1 | - |
| Ascension Via Christi Hospitals Wichita | - | - | 1 | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - | 3 |
| Cancer Research Consortium of West Michigan NCORP | - | - | 146 | - | - |
| Cancer Research for the Ozarks NCORP | - | - | 10 | 1 | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | - | - | 9 | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | - | 6 | - | - |
| City of Hope Comprehensive Cancer Center | 2 | - | - | - | - |
| Columbia University Minority Underserved NCORP | - | - | 27 | - | - |
| Columbus NCI Community Oncology Research Program | - | - | - | 1 | - |
| CommonSpirit Health Research Institute | - | - | 71 | 1 | - |
| Dayton NCI Community Oncology Research Program | - | - | - | - | - |
| Desert Regional Medical Center | - | - | 3 | - | - |
| Fred Hutchinson Cancer Research Center LAPS | 7 | - | - | - | - |
| Georgia NCI Community Oncology Research Program | - | - | 18 | - | - |
| Grupo Oncologico Cooperativo de Investigacion | - | - | 10 | - | - |
| Gulf South Minority Underserved NCORP | 1 | - | 26 | - | 1 |
| Hawaii Minority Underserved NCORP | - | - | 70 | - | - |
| Heartland Cancer Research NCORP | - | - | 38 | 10 | - |
| Henry Ford Hospital | 7 | - | - | - | - |
| Instituto Nacional De Cancerologia | - | - | 10 | - | - |
| Instituto Nacional De Cancerologia de Mexico | - | - | 60 | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | - | 2 | 65 | - | - |
| Lahey Hospital and Medical Center | - | - | 22 | 6 | - |
| Loyola University Medical Center | - | - | 2 | - | - |
| Medical University of South Carolina Minority Underserved NCORP | - | - | - | - | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | - | 30 | - | - |
| Northwell Health NCORP | - | - | - | - | 2 |
| Pacific Cancer Research Consortium NCORP | - | - | 2 | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | - | 278 | 3 | - |
| The West Clinic - Wolf River | - | - | - | - | 6 |
| Tulane University Health Sciences Center | - | - | 1 | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | - | - | - | 1 |
| USC Norris Comprehensive Cancer Center LAPS | 58 | - | - | - | - |
| University of Arkansas for Medical Sciences | - | - | 68 | - | - |
| University of Colorado Cancer Center LAPS | 2 | - | 2 | - | 16 |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 32 | - | 24 | - | - |
| University of Kentucky/Markey Cancer Center | - | - | - | - | - |
| University of Rochester LAPS | 6 | - | - | - | - |
| University of Texas Health Science Center at San Antonio | - | - | 14 | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | - | - | - | - | - |
| Upstate Carolina Consortium Community Oncology Research Program | - | - | 118 | - | 1 |
| Wayne State University - Karmanos Cancer Institute LAPS | - | - | - | - | - |
| ALLIANCE | 5 | - | 44 | 9 | - |
| ECOG-ACRIN | - | - | 80 | 7 | - |
| NRG | 1 | 1 | 90 | 9 | - |
| Total | 121 | 3 | 1,336 | 57 | 30 |

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | A221602 | A221702 | A221805 | EAZ171 |
|---|-----------|-----------|----------|----------|
| Ascension Providence Hospitals - Southfield | - | - | - | - |
| Ascension Via Christi Hospitals Wichita | - | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - |
| Cancer Research Consortium of West Michigan NCORP | - | - | - | - |
| Cancer Research for the Ozarks NCORP | - | - | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | - | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | - | - | - |
| City of Hope Comprehensive Cancer Center | - | - | - | - |
| Columbia University Minority Underserved NCORP | 3 | - | - | - |
| Columbus NCI Community Oncology Research Program | - | - | - | - |
| CommonSpirit Health Research Institute | - | - | - | - |
| Dayton NCI Community Oncology Research Program | 1 | - | 1 | - |
| Desert Regional Medical Center | 3 | - | - | - |
| Fred Hutchinson Cancer Research Center LAPS | - | - | - | - |
| Georgia NCI Community Oncology Research Program | - | - | - | - |
| Grupo Oncologico Cooperativo de Investigacion | - | - | - | - |
| Gulf South Minority Underserved NCORP | - | - | - | 1 |
| Hawaii Minority Underserved NCORP | - | - | - | - |
| Heartland Cancer Research NCORP | - | - | - | - |
| Henry Ford Hospital | - | - | - | - |
| Instituto Nacional De Cancerologia | - | - | - | - |
| Instituto Nacional De Cancerologia de Mexico | - | - | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | - | - | - | - |
| Lahey Hospital and Medical Center | - | - | - | - |
| Loyola University Medical Center | - | - | - | - |
| Medical University of South Carolina Minority Underserved NCORP | - | - | - | 2 |
| NCORP of the Carolinas (Prisma Health NCORP) | - | - | - | - |
| Northwell Health NCORP | 3 | - | - | - |
| Pacific Cancer Research Consortium NCORP | - | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | - | - | - |
| The West Clinic - Wolf River | - | - | - | - |
| Tulane University Health Sciences Center | - | - | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | 4 | - | - | - |
| USC Norris Comprehensive Cancer Center LAPS | - | - | - | - |
| University of Arkansas for Medical Sciences | - | - | - | - |
| University of Colorado Cancer Center LAPS | - | - | 2 | - |
| University of Kansas Cancer Center - MCA Rural MU NCORP | - | - | 1 | - |
| University of Kentucky/Markey Cancer Center | 10 | - | - | - |
| University of Rochester LAPS | - | 14 | - | - |
| University of Texas Health Science Center at San Antonio | - | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 8 | - | - | - |
| Upstate Carolina Consortium Community Oncology Research Program | - | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | 1 | - | - |
| ALLIANCE | - | - | - | - |
| ECOG-ACRIN | - | - | - | - |
| NRG | - | - | - | - |
| Total | 32 | 15 | 4 | 3 |

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
Vice-Chair: Young Kwang Chae, MD, MPH
Executive Officer: Christopher W. Ryan, MD
Statisticians: Megan Othus, PhD
..... Melissa Plets, MS
..... Edward Mayerson, MS

Designates

Data Coordinators: Christine Magner
Digital Engagement: Kanwal Raghav, MD, MBBS
Oncology Research Professionals:
CRAs: TBD
Nurse: TBD
Pharmaceutical Science: Craig Elg, PharmD
..... Sun "Coco" Yang, PharmD, PhD
Patient Advocate: Marcia K. Horn, JD
Protocol Project Manager: Catrina Mireles
Clinical Trials Program Manager: Michelle Maxim
Early Therapeutics Liaisons
Breast Committee Liaison: TBD
Cancer Control Liaison: Jason M. Prosek, MD
Genitourinary Committee Liaison: Neeraj Agarwal, MD
Imaging: TBD
Lung Committee Liaison: Shirish M. Gadgeel, MD
Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
Melanoma Committee Liaison: Jeffrey A. Sosman, MD
Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, April 7, 2022 10:00 am - 12:15 pm
Room: Columbia D, Level 3

Agenda

Introduction

10:00 - 10:05 am: Razelle Kurzrock, M.D., Chair, Early Therapeutics and Rare Cancer Committee (SWOG).

Presentations

10:05 - 10:20 am: "Updates from Sarcoma Working Group" - Lara Davis, M.D., Associate Professor Knight Cancer Institute, Co-Leader, Translational Oncology Research Program, Sarcoma Disease Site Leader, Knight Cancer Institute, Oregon Health & Science University.

10:20 - 10:35 am: "Update on Sarcoma Concept" - Michael Wagner, M.D., Assistant Professor, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center.

10:35 - 10:55 am: "Updates from CNS Working Group." - Manmeet Ahluwalia, M.D., Chief of Medical Oncology, Deputy Director, Chief Scientific Officer, Miami Cancer Institute.

10:55 - 11:15 am: "CIMAC and Translational Immunology in DART." - Young Chae, M.D., Vice Chair, Early Therapeutics and Rare Cancers (SWOG), Northwestern University, Robert H. Lurie Comprehensive Cancer Center.

11:15 - 11:35 am: "DART: Clinical Trial Updates." - Sandip Patel, M.D., Associate Professor Deputy Director, San Diego Center for Precision Immunotherapy, UC San Diego Moores Comprehensive Cancer Center, San Diego, CA

11:35 - 11:55 am: "New Drugs in Oncology." - Monica Mita, M.D., Professor of Medicine, Co-Director, Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center.

11:55 am - 12:10 pm: "New Approved Study: S2012, Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)" - David Zhen, M.D., Assistant Professor of Medicine, University of Washington, Fred Hutchinson Cancer Research Center.

12:10 - 12:15 pm: Wrap Up. Razelle Kurzrock, M.D., Chair, Early Therapeutics and Rare Cancer Committee (SWOG).

Active Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015.

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma." Dr. Dunn. Activated: 10/30/20.

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigette B. Y. Activated: 9/8/20; Temporarily Closed: 10/28/21

Early Therapeutics & Rare Cancers Committee

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20.

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Temporarily Closed: 6/15/21.

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18.

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

Proposed Studies

S2208, "Neoadjuvant Nivolumab and Paclitaxel Followed by Definitive Local Control for Patients with Locoregional Angiosarcoma." Dr. Wagner.

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG, SWOG study in HPV-associated malignancies by the use of AZD2811, an Aurora B kinase inhibitor, and MEDI4736, anti-PD-L1. Dr. Fu.

Closed Studies

NCIC019, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Ceirbhail. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG, SWOG study in HPV-associated malignancies by the use of AZD2811, an Aurora B kinase inhibitor, and MEDI4736, anti-PD-L1. Dr. Fu.

We have welcomed a number of new patient advocates since our last in-person meeting!

Roberta Albany, research advocate, breast cancer | **Janice Choe**, community advocate, Asian/Pacific Islander community | **Valerie Fraser**, research advocate, palliative and end-of-life care | **Eileen Z. Fuentes, MA**, community advocate, Latinx community | **Samantha Guild, JD**, research advocate, melanoma | **Howard Krongard, JD**, community advocate, older adult cancer community | **Joël Pointon, MSPH**, community advocate, LGBTQ community | **Allison Rosen**, research advocate, adolescent & young adult cancer | **Lauren Wagner**, community advocate, adolescent & young adult community | **Desirée A.H. Walker**, research advocate, recruitment & retention | **Bruce A. Wright**, community advocate, military veterans community



Introduce yourself to your SWOG patient advocates today!

Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | 51609 | AGCT1531 | EAY131 |
|---|-------|----------|--------|
| Ascension Providence Hospitals - Southfield | 1 | - | 3 |
| Baptist Memorial Health Care/Mid South Minority Underserved NCORP | 2 | - | - |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | - | - | 3 |
| CWRU Case Comprehensive Cancer Center LAPS | 6 | - | 10 |
| Cancer Research for the Ozarks NCORP | 1 | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | 3 | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | 3 | - | - |
| Cedars-Sinai Medical Center | 8 | - | 6 |
| City of Hope Comprehensive Cancer Center | 2 | - | 6 |
| Columbus NCI Community Oncology Research Program | 3 | - | - |
| CommonSpirit Health Research Institute | 17 | - | 9 |
| Dayton NCI Community Oncology Research Program | 2 | - | 1 |
| Essentia Health NCI Community Oncology Research Program | 4 | - | - |
| Fred Hutchinson Cancer Research Center LAPS | 10 | - | 2 |
| Georgia NCI Community Oncology Research Program | 6 | - | - |
| Gulf South Minority Underserved NCORP | 2 | - | - |
| Hawaii Minority Underserved NCORP | 3 | - | 1 |
| Heartland Cancer Research NCORP | 15 | - | 1 |
| Henry Ford Hospital | 17 | - | 11 |
| Houston Methodist Hospital | - | - | 1 |
| Intermountain Medical Center | 1 | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | 27 | - | 6 |
| Loma Linda University Medical Center | 6 | - | 1 |
| Loyola University Medical Center | 4 | - | - |
| Massachusetts Veterans Epidemiology Research and Information Center | 5 | - | - |
| Medical University of South Carolina Minority Underserved NCORP | 4 | - | 2 |
| Michigan Cancer Research Consortium NCORP | 12 | - | - |
| Moffitt Cancer Center | 22 | - | - |
| Montana Cancer Consortium NCORP | 16 | - | - |
| MultiCare Tacoma General Hospital | 2 | - | - |
| Nevada Cancer Research Foundation NCORP | 18 | - | - |
| New Mexico Minority Underserved NCORP | 17 | - | - |

Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1609 | AGCT1531 | EAY131 |
|---|------------|----------|------------|
| Northwestern University LAPS | 16 | - | - |
| Oregon Health and Science University | 11 | - | - |
| Pacific Cancer Research Consortium NCORP | 12 | - | - |
| Saint Luke's Hospital of Kansas City | - | - | 1 |
| Southeast Clinical Oncology Research Consortium NCORP | - | - | 8 |
| Sutter Cancer Research Consortium | 2 | - | 4 |
| The Don and Sybil Harrington Cancer Center | - | 1 | - |
| Tulane University Health Sciences Center | - | - | 1 |
| UC Davis Comprehensive Cancer Center LAPS | 11 | - | 9 |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | 8 | - | 19 |
| UC San Diego Moores Cancer Center | 27 | - | - |
| USC Norris Comprehensive Cancer Center LAPS | 4 | - | - |
| University of Arkansas for Medical Sciences | 5 | - | 3 |
| University of Colorado Cancer Center LAPS | 6 | - | 9 |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 35 | - | 6 |
| University of Kentucky/Markey Cancer Center | - | - | 13 |
| University of Michigan Comprehensive Cancer Center LAPS | 32 | - | 24 |
| University of Mississippi Medical Center | 5 | - | - |
| University of Oklahoma Health Sciences Center LAPS | 2 | - | - |
| University of Rochester LAPS | 5 | - | - |
| University of Texas Health Science Center at San Antonio | 5 | - | 7 |
| University of Texas MD Anderson Cancer Center LAPS | 19 | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 3 | - | - |
| Upstate Carolina Consortium Community Oncology Research Program | 4 | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | - | 3 |
| Wisconsin NCI Community Oncology Research Program | 12 | - | - |
| Yale University - Yale Cancer Center LAPS | 7 | - | 13 |
| ALLIANCE | 105 | - | - |
| ECOG-ACRIN | 78 | - | - |
| NRG | 136 | - | - |
| Total | 789 | 1 | 183 |

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena G. Chiorean, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Shay Bellasea, MS

Scientific Leadership

Phase I Studies: Sandip P. Patel, MD
 Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Elena Gabriela Chiorean, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed Ahmad, MD (Surgical representative)
 Colon: Philip J. Gold, MD
 Wells A. Messersmith, MD
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Jonathan R. Strosberg, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Translational Medicine: Heinz-Josef Lenz, MD
 Christopher H. Lieu, MD
 Daniel Catenacci, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Jeremiah Lee Deneve, DO (Surgical)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 Chan Shen, PhD, MS (Health Outcomes)
 Mark A. O'Rourke, MD (Palliative Care)
 Digital Engagement: Heloisa Soares, MD, PhD
 Data Coordinators: Christine Magner
 Brian Zeller
 Ojasvi Mittal

Oncology Research Professionals:

CRA: Sandy Annis, CCRP
 Nurse: TBD
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Patient Advocate (Colon): Florence Kurttila, MS
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Protocol Project Manager: Christy Klepetko
 Clinical Trials Program Manager: Michelle Maxim

Time/Location

Friday, April 8, 2022 3:00 - 5:00 pm
 Room: Elwha B, Level 5

Agenda

1. Welcome

2. Announcements & Introductions

3. SWOG led trials (15 minutes)

- | | |
|--------------------------|----------------|
| a. S2104 | Soares, Ahmed |
| b. S2107 | Morris, Kopetz |
| c. S2001 | Chung |

4. Select NCTN Studies championed by SWOG (25 minutes)

- | | |
|---|---------|
| a. EA2174 perioperative eso/GEJ | Kelly |
| b. A021806 perioperative PDA | Behrman |
| c. EA2192 adjuvant PDA | Kasi |
| d. EA2176 1st line met anal | Morris |
| e. EA2197 perioperative gallbladder | Rocha |

Gastroesophageal Cancers (12 minutes) Iqbal, Wainberg

- Recent highlights
- Ongoing NCTN studies
- Future plans

Hepatobiliary (12 minutes) El-Khoueiry, Shroff

- Recent highlights
- Ongoing NCTN studies
- Future plans

Gastrointestinal Committee

Pancreatic (12 minutes)

Lowy, Sohal

closed: 06/15/21.

- a. Recent highlights
- b. Ongoing NCTN studies
- c. Future plans

Colon (12 minutes)

Fakih, Gold, Gholami

- a. Recent highlights
- b. Ongoing NCTN studies
- c. Future plans

Anal and Rectal (12 minutes)

Kachnic, Kennecke

- a. Recent highlights
- b. Ongoing NCTN studies
- c. Future plans

Neuroendocrine (12 minutes)

Strosberg, Dasari

- a. Recent highlights
- b. Ongoing NCTN studies
- c. Future plans

5. Patient advocates (5 minutes)

6. Other business

7. Adjourn

Gastroesophageal

Proposed Studies

S2214, "A Randomized Phase II Trial of Perioperative Trastuzumab and Atezolizumab given with FLOT or FOLFOX vs. FLOT or FOLFOX alone in Resectable HER2-Overexpressing Gastric/GEJ Adenocarcinoma." Dr. Chao.

Active Studies

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020. Temporarily

Pancreatic

Active Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

Proposed Studies

S2211, "Randomized Phase II/III Study of Gemcitabine and nab-paclitaxel with and without CEND-1 for 1st Line Treatment of Metastatic Pancreatic Cancer." Dr. Botta.

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18.

Hepatobiliary

Proposed Studies

Gastrointestinal Committee

S2109, "A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab for Patients with Resectable Hepatocellular Carcinoma." Dr. Kaseb.

Active Studies

CTSU/NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

CTSU/EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

CTSU/EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Temporarily closed: 03/31/21.

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

Colorectal

Proposed Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris.

Active Studies

CTSU/NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. Scott. Activated: 12/16/19.

CTSU/A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19.

CTSU/A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17.

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H)

Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13.

Closed Studies

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 1 closed to accrual: 1/1/2022.

Anal

Active Studies

CTSU/EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

CTSU/EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

CTSU/EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Dr. Cho. Activated 5/13/21.

Other

Active Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Dr. Overman. Activated: 12/16/19.

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Dr. Patel. Activated 1/13/17.

EAY131, "Molecular Analysis for Therapy Choice." Dr. Villalobos. Activated: 8/12/15.

Gastrointestinal Committee


Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1613 | S1815 | S1922 | S2001 | A021502 | A021602 | A021703 | A021806 | EA2142 | EA2165 |
|---|-------|-------|-------|-------|---------|---------|---------|---------|--------|--------|
| Ascension Prov Hospitals - Southfield | - | - | - | 1 | 2 | - | - | - | - | 1 |
| Ascension Via Christi Hospitals Wichita | - | 1 | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | - | 13 | - | - | 2 | - | - | 1 | - | - |
| Baylor Coll Med/Dan L Duncan CCC | - | 6 | - | - | - | - | - | - | - | - |
| Boston Med Ctr | - | - | - | - | 1 | 3 | - | 1 | - | 1 |
| CWRU Case CCC LAPS | - | - | - | - | 3 | - | - | 1 | - | - |
| Ca Res Consortium West Mich NCORP | - | 2 | - | - | - | - | - | - | - | - |
| Ca Res for the Ozarks NCORP | - | 3 | - | - | - | - | - | - | - | - |
| Ca Res of Wisconsin & N Mich Consort | - | 2 | - | - | - | - | - | - | - | - |
| City of Hope CCC | - | 4 | - | 1 | - | 1 | - | - | - | - |
| Columbus NCORP | - | 3 | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | 3 | 4 | - | - | - | - | - | - | - | - |
| Dayton NCORP | - | 2 | - | - | 3 | - | - | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | - | - | - | - | 3 | - | - | - | - | 3 |
| Gulf South MU NCORP | - | 4 | - | - | - | - | - | - | - | 1 |
| Hawaii MU NCORP | - | 11 | - | - | - | - | - | - | - | - |
| Heartland Ca Res NCORP | 3 | 7 | - | - | - | - | - | - | - | - |
| Henry Ford Hospital | - | 2 | - | - | - | - | - | - | 1 | - |
| Kaiser Permanente NCORP | 2 | - | - | - | 14 | - | - | - | 2 | 6 |
| Lahey Hospital & Med Ctr | 1 | - | - | - | - | - | - | - | - | - |
| Loyola U Med Ctr | 1 | - | - | - | - | - | - | - | - | - |
| Michigan Ca Res Consortium NCORP | 1 | - | 1 | - | - | - | - | - | - | - |
| Moffitt CC | - | - | - | - | - | 4 | - | - | - | - |
| Montana Cancer Consortium NCORP | - | 4 | - | - | - | - | - | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | - | 11 | - | - | - | - | - | - | - | 1 |
| New Mexico MU NCORP | - | 9 | - | - | - | - | - | - | - | - |
| Northwell Health NCORP | - | - | - | - | - | - | 6 | 1 | - | - |
| Northwestern U LAPS | 1 | 17 | 1 | - | - | - | 4 | - | - | - |
| Oregon Health & Science U | - | 3 | - | - | - | - | - | - | - | 4 |

Our History

Founded in 1956 by the National Cancer Institute, we are part of the NCI's National Clinical Trials Network, the largest and oldest publicly funded cancer research network in the United States. We are also part of NCI's Community Oncology Research Program, which connects us to community hospitals and clinics across the nation – and the diverse populations they serve.


Dr. Grant Taylor,
first SWOG
group chair



Gastrointestinal Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1613 | S1815 | S1922 | S2001 | A021502 | A021602 | A021703 | A021806 | EA2142 | EA2165 |
|---------------------------------------|-----------|------------|-----------|----------|-----------|-----------|-----------|-----------|----------|-----------|
| Pacific Ca Res Consortium NCORP | 3 | 9 | - | - | - | - | - | - | - | - |
| SCL Health Saint Joseph Hospital | - | - | - | - | - | - | - | - | - | 1 |
| Southeast Clin Onc Res Consort NCORP | 1 | 1 | - | 1 | - | - | - | - | - | - |
| Sutter Ca Res Consortium | - | - | - | - | 3 | - | - | - | - | 2 |
| West Clinic - Wolf River | - | 1 | - | - | - | - | - | - | - | - |
| UC Davis CCC LAPS | 2 | 4 | - | - | 4 | - | - | - | - | 5 |
| UC Irvine Health/Chao Family CCC | - | 3 | - | - | - | - | - | - | - | - |
| USC Norris CCC LAPS | 1 | 9 | - | - | 1 | - | 1 | - | - | - |
| U Alabama Birm/Deep South RC LAPS | - | - | - | - | - | - | - | - | - | 1 |
| U Arkansas for Medical Sciences | - | 2 | - | - | - | - | - | - | - | 7 |
| U Cincinnati CC-UC Med Ctr | - | 2 | - | - | - | - | 3 | - | - | 1 |
| U Colorado CC LAPS | 1 | - | - | - | 6 | - | 1 | - | - | - |
| U Kansas CC - MCA Rural MU NCORP | 4 | - | - | - | 3 | - | 1 | - | - | - |
| U Michigan CCC LAPS | 1 | 3 | 2 | - | - | 2 | - | 4 | 3 | - |
| U Rochester LAPS | - | 9 | 1 | - | 2 | 4 | - | 2 | - | - |
| U Texas HSC at San Antonio | - | 1 | - | - | - | - | - | 3 | - | - |
| U Texas MD Anderson CC LAPS | 13 | 22 | 5 | - | - | - | - | - | - | - |
| U Utah - Huntsman Ca Inst LAPS | - | 5 | - | 1 | - | - | - | - | - | - |
| Upstate Carolina Consortium NCORP | - | 1 | - | - | - | - | - | - | - | - |
| Vanderbilt U - Ingram CC LAPS | - | 4 | - | - | - | - | - | - | - | - |
| Virginia Mason Med Ctr | - | - | - | - | 4 | 2 | - | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | 2 | - | - | 2 | - | - | - | - | 3 |
| William Beaumont Hosp-Royal Oak | - | - | - | - | 1 | - | - | - | - | - |
| Wisconsin NCORP | - | 1 | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | - | 10 | - | - | 2 | - | 3 | - | - | - |
| ALLIANCE | 6 | 122 | 6 | 1 | - | - | - | - | - | - |
| ECOG-ACRIN | 4 | 92 | 1 | - | - | - | - | - | - | - |
| NRG | 5 | 41 | 2 | - | - | - | - | - | - | - |
| Total | 53 | 452 | 19 | 5 | 56 | 16 | 19 | 13 | 6 | 37 |



Where We Are

- 1 The Hope Foundation for Cancer Research, Ann Arbor, MI
- 2 Fred Hutch Cancer Research Center and Cancer Research And Biostatistics, Seattle, WA
- 3 SWOG Group Chair's Office, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
- 4 SWOG Operations, San Antonio, TX

Gastrointestinal Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | EA2174 | EA2176 | EA2186 | EA2187 | EA2197 | NRGG005 |
|---|--------|----------|----------|----------|----------|----------|
| <i>Ascension Prov Hospitals - Southfield</i> | - | - | 2 | - | - | 1 |
| <i>Ascension Via Christi Hospitals Wichita</i> | - | - | - | - | - | - |
| <i>Banner U Med Ctr - Tucson</i> | - | - | - | - | - | - |
| <i>Baylor Coll Med/Dan L Duncan CCC</i> | - | - | - | - | - | - |
| <i>Boston Med Ctr</i> | - | - | - | - | - | - |
| <i>CWRU Case CCC LAPS</i> | - | - | - | 3 | - | - |
| <i>Ca Res Consortium West Mich NCORP</i> | - | - | - | - | - | - |
| <i>Ca Res for the Ozarks NCORP</i> | - | - | - | - | - | - |
| <i>Ca Res of Wisconsin & N Mich Consort</i> | - | - | - | - | - | - |
| <i>City of Hope CCC</i> | - | - | 1 | - | - | - |
| <i>Columbus NCORP</i> | - | - | - | - | - | - |
| <i>CommonSpirit Health Research Inst</i> | - | - | - | - | - | - |
| <i>Dayton NCORP</i> | - | - | - | - | - | - |
| <i>Fred Hutchinson Ca Res Ctr LAPS</i> | - | - | - | - | - | - |
| <i>Gulf South MU NCORP</i> | - | - | - | - | - | - |
| <i>Hawaii MU NCORP</i> | - | - | 2 | - | - | - |
| <i>Heartland Ca Res NCORP</i> | - | - | - | - | - | - |
| <i>Henry Ford Hospital</i> | - | - | - | - | - | 1 |
| <i>Kaiser Permanente NCORP</i> | - | 2 | - | - | - | 4 |
| <i>Lahey Hospital & Med Ctr</i> | - | - | - | - | - | - |
| <i>Loyola U Med Ctr</i> | - | - | - | - | - | - |
| <i>Michigan Ca Res Consortium NCORP</i> | - | - | - | - | - | - |
| <i>Moffitt CC</i> | - | - | - | - | - | - |
| <i>Montana Cancer Consortium NCORP</i> | - | - | - | - | - | - |
| <i>NCORP Carolinas (Prisma Hlth NCORP)</i> | - | - | - | - | - | - |
| <i>New Mexico MU NCORP</i> | - | - | - | - | - | - |
| <i>Northwell Health NCORP</i> | - | - | 1 | - | - | - |
| <i>Northwestern U LAPS</i> | - | - | 1 | - | - | - |
| <i>Oregon Health & Science U</i> | - | - | - | - | 1 | - |

Gastrointestinal Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | EA2174 | EA2176 | EA2186 | EA2187 | EA2197 | NRGG1005 |
|---------------------------------------|----------|----------|-----------|----------|----------|-----------|
| Pacific Ca Res Consortium NCORP | - | - | - | - | - | - |
| SCL Health Saint Joseph Hospital | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | - | - | - | - | - | - |
| Sutter Ca Res Consortium | - | - | - | 1 | - | - |
| West Clinic - Wolf River | - | - | - | - | - | - |
| UC Davis CCC LAPS | - | - | - | - | - | 1 |
| UC Irvine Health/Chao Family CCC | - | - | - | - | - | - |
| USC Norris CCC LAPS | 1 | - | - | - | - | - |
| U Alabama Birm/Deep South RC LAPS | - | - | - | - | - | - |
| U Arkansas for Medical Sciences | - | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | - | - | - | - | - |
| U Colorado CC LAPS | - | - | 1 | - | - | - |
| U Kansas CC - MCA Rural MU NCORP | - | - | - | 1 | - | 1 |
| U Michigan CCC LAPS | - | - | - | - | - | - |
| U Rochester LAPS | - | - | 4 | 2 | - | - |
| U Texas HSC at San Antonio | - | - | 2 | - | - | - |
| U Texas MD Anderson CC LAPS | - | 3 | - | - | - | 1 |
| U Utah - Huntsman Ca Inst LAPS | - | - | - | - | - | - |
| Upstate Carolina Consortium NCORP | - | - | - | - | - | - |
| Vanderbilt U - Ingram CC LAPS | - | - | - | - | - | - |
| Virginia Mason Med Ctr | - | - | - | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | - | - | - | - | - |
| William Beaumont Hosp-Royal Oak | - | - | - | - | - | - |
| Wisconsin NCORP | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | - | - | - | - | - | 4 |
| ALLIANCE | - | - | - | - | - | - |
| ECOG-ACRIN | - | - | - | - | - | - |
| NRG | - | - | - | - | - | - |
| Total | 1 | 5 | 14 | 7 | 1 | 13 |

Genitourinary Committee

Leadership

Chair: Ian M. Thompson, Jr, MD
Vice-Chair: Daniel P. Petrylak, MD
Executive Officer: Christopher W. Ryan, MD
Statisticians: Cathy M. Tangen, DrPH
..... Melissa Plets, MS
..... Eddie Mayerson, MS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
..... Joshua J. Meeks, MD, PhD (Bladder)
..... Amir Goldkorn, MD (Prostate)
..... Sumanta "Monty" K. Pal, MD (Renal)
Radiation Oncology: James B. Yu, MD
..... Daniel A. Hamstra, MD
Imaging: Evan Y. Yu, MD
..... Hiram Shaish, MD
..... John D. Hazle, PhD
Pathology: M. Scott Lucia, MD
Surgery: Kelly L. Stratton, MD
Liaison to the SPORES: Colin P.N. Dinney, MD
Early Therapeutics: Neeraj Agarwal, MD
Bladder Organ Site Chairs: Seth P. Lerner, MD (Localized)
..... Thomas W. Flaig, MD (Localized)
..... Daniel P. Petrylak, MD (Advanced)
Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
..... David I. Quinn, MD, PhD (Advanced)
Renal Organ Site Chairs: Brian Shuch, MD (Localized)
..... Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Peter J. Van Veldhuizen, Jr, MD
Digital Engagement: Neema Navai, MD
Veterans Affairs Michael M. Goodman, MD
Data Coordinators: Jeri Jardine
..... Tonya Johnson
..... Michele Counts
..... Laura Wells
Oncology Research Professionals:
CRAs: Abigail L. Cornette, MS
..... Cheryl Farlow, RN, OCN
Nurses: Deborah A. Shaw, RN
..... Cheryl Kefauver, RN
Patient Advocates: Rick Bangs, MBA (Bladder)
..... Tony Crispino (Prostate)

..... Margaret "Peggy" Zuckerman, MEd (Renal)
Pharmaceutical Science: Joyce Lee, PharmD
..... Allison Schepers, PharmD
Protocol Project Manager: Taj Pereira
Clinical Trials Program Manager: TBD

Time/Location

GU Committee Part I: Friday, April 8, 2022 3:15 - 6:15 pm
Room: Columbia CD, Level 3

Time/Location

GU Committee Part II: Saturday, April 9, 2022 8:30 - 11:30 am
Room: Columbia CD, Level 3

Agenda

GU Committee Part I

3:15 – 3:30 – Chair's Welcome and Opening Remarks. Ian Thompson
3:30 – 4:45 – Renal Organ site. (Dr Ulka Vaishampayan and Dr. Brian Shuch)
4:45 – 5:55 – Translational Medicine (Dr. David McConkey)
5:55 – 6:15 – Cancer Control (Dr Peter Van Veldhuizen)

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Ne-phrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Initial protocol submission to CTEP: 1/21/22.

Active Studies

CTSU/AREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

Genitourinary Committee

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

Active Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, E, F, G, I.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subproto-cols A, C1, C2, E, L, V, Z1E, and Z1 are closed to accrual: 1/31/22.

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Agenda

GU Committee Part II

8:30-9:45 – Bladder Organ Site (Drs Seth Lerner and Thomas Flaig)

9:45-11:30 – Prostate Organ Site (Drs. Tanya Dorff and Daniel Lin)

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Seth Lerner (Local).

Priority Study

S2011, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde M. Liss, and S. Lerner, et al. Activated: 10/6/21.

Genitourinary Committee

Active Studies

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efsthathiou, et al. Activated: 4/19/19.

CTSU/A031701, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

Closed Studies

S1011, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

S1602, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or

Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

Concepts in Development

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Concept submission to CTEP: 2/8/22.

Active Studies

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Re-lapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17.

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk

Genitourinary Committee

and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*).” Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

CTSU/RTOG-0924, “Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, “Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Acti- vated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1

additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21.

CTSU/NRG-GU008, “Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate

Cancer by Varying the Hormonal Therapy.” Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21


CTSU/EA8153, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

Get the Scoop!

Want the Front Line blog every Friday?

Or the Translational Medicine Link of the Week?

How about the Hope Foundation Monthly E-Newsletter?



Email communications@swog.org to get on a list – one or all three

Genitourinary Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1602 | S1802 | S1806 | S1931 | S1937 | A031102 | A031501 | A031701 | A031702 | A031704 | A031801 | A031803 | A031902 | EA8134 | EA8143 |
|---------------------------------------|-------|-------|-------|-------|-------|---------|---------|---------|---------|---------|---------|---------|---------|--------|--------|
| Ascension Prov Hospitals - Southfield | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Banner MD Anderson CC | 7 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | - | 6 | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 |
| Baylor Coll Med/Dan L Duncan CCC | 21 | 1 | 2 | - | - | - | 1 | - | - | - | - | - | - | - | 1 |
| CWRU Case CCC LAPS | - | - | - | - | - | - | - | 4 | - | - | - | - | 2 | - | - |
| Ca Res Consortium West Mich NCORP | - | 2 | 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Ca Res for the Ozarks NCORP | 10 | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Ca Res of Wisconsin & N Mich Consort | - | 1 | 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Cedars-Sinai Med Ctr | 12 | - | 5 | 1 | - | - | - | - | - | - | - | - | - | - | 8 |
| City of Hope CCC | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Columbia U MU NCORP | - | - | 1 | - | - | - | 3 | - | - | - | - | - | - | - | 1 |
| CommonSpirit Health Research Inst | - | - | 2 | - | 1 | - | - | - | - | - | - | - | - | - | 4 |
| Cotton O'Neil CC / Stormont Vail Hlth | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - |
| Dayton NCORP | 1 | 3 | - | - | - | - | - | - | - | 1 | - | - | - | - | 1 |
| Fred Hutchinson Ca Res Ctr LAPS | 26 | 8 | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
| Georgia Cares MU NCORP | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gulf South MU NCORP | 95 | 60 | 40 | - | - | - | 2 | - | - | - | 1 | 9 | - | - | 10 |
| Hawaii MU NCORP | 9 | - | 2 | - | - | - | - | - | - | - | - | - | - | - | 2 |
| Heartland Ca Res NCORP | 4 | 8 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| Henry Ford Hospital | 13 | 16 | 3 | - | - | - | 1 | - | 1 | 5 | - | - | - | - | 3 |
| Houston Methodist Hospital | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Kaiser Permanente NCORP | 12 | 14 | - | - | - | - | 14 | - | - | 40 | - | - | - | - | 41 |
| Lahey Hospital & Med Ctr | - | - | - | - | - | - | 4 | - | 6 | - | - | - | - | - | 4 |
| Loma Linda U Med Ctr | - | - | - | - | - | - | 2 | - | - | - | - | - | - | - | - |
| Loyola U Med Ctr | 12 | 9 | 4 | - | - | - | - | - | 1 | 1 | - | - | - | - | 4 |
| Massachusetts Veterans ERIC | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - |
| Medical U South Carolina MU NCORP | 2 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Michigan Ca Res Consortium NCORP | 6 | 7 | 9 | - | 1 | - | - | - | - | - | - | - | - | - | - |
| Moffitt CC | 26 | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
| Montana Cancer Consortium NCORP | 1 | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | 1 | 6 | - | - | - | - | - | - | - | 1 | - | - | - | - | 1 |
| Nevada Ca Res Foundation NCORP | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | 2 |
| New Mexico MU NCORP | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Northwell Health NCORP | - | - | 1 | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Northwestern U LAPS | 35 | - | 6 | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Ohio State U CCC LAPS | 4 | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |

Genitourinary Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1602 | S1802 | S1806 | S1931 | S1937 | A031102 | A031501 | A031701 | A031702 | A031704 | A031801 | A031803 | A031902 | EA8134 | EA8143 |
|---------------------------------------|--------------|------------|------------|-----------|----------|-----------|-----------|----------|-----------|-----------|----------|-----------|----------|----------|------------|
| Oregon Health & Science U | 14 | - | 1 | - | - | - | - | - | 3 | 3 | - | - | - | - | 14 |
| Pacific Ca Res Consortium NCORP | 24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SCL Health Saint Joseph Hospital | - | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | - | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sutter Ca Res Consortium | - | - | 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Tulane U Health Sciences Ctr | - | - | - | 4 | - | - | - | - | - | - | - | - | - | - | 10 |
| UC Davis CCC LAPS | - | 9 | 7 | - | - | - | 4 | 4 | - | 2 | 2 | 3 | - | - | 1 |
| UC Irvine Health/Chao Family CCC | 16 | 2 | 3 | - | - | - | - | - | - | - | - | - | - | - | 1 |
| UC San Diego Moores CC | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 2 |
| UCLA / Jonsson CCC | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8 |
| USC Norris CCC LAPS | 44 | 5 | - | - | 2 | 11 | 13 | - | 3 | - | - | - | - | 8 | - |
| U Alabama Birm/Deep South RC LAPS | - | - | - | - | - | - | - | - | 1 | - | 1 | 1 | - | - | 6 |
| U Arkansas for Medical Sciences | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | 4 | 3 | 1 | - | - | - | - | - | 6 | - | - | - | - | - |
| U Colorado CC LAPS | 23 | 4 | 2 | - | - | - | 13 | - | - | 7 | - | - | - | - | 1 |
| U Kansas CC - MCA Rural MU NCORP | 20 | 7 | 4 | - | - | - | 5 | - | 1 | 4 | - | - | - | - | 2 |
| U Kentucky/Markey CC | - | - | 2 | - | - | - | - | - | - | - | - | - | - | - | 12 |
| U Michigan CCC LAPS | 30 | 2 | - | 5 | - | - | 18 | - | - | - | - | - | - | - | - |
| U Mississippi Med Ctr | - | 1 | - | - | - | - | - | - | 1 | - | - | - | - | - | 3 |
| U Oklahoma Health Sciences Ctr LAPS | 51 | 25 | 14 | 2 | - | - | - | - | - | - | - | - | - | - | - |
| U Rochester LAPS | 20 | 17 | - | - | - | - | - | - | 3 | 5 | - | - | - | - | 1 |
| U Texas HSC at San Antonio | 58 | 2 | - | 1 | - | - | - | - | - | - | - | 4 | - | - | 14 |
| U Texas MD Anderson CC LAPS | 38 | 61 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| U Utah - Huntsman Ca Inst LAPS | 47 | 15 | - | 1 | - | - | 3 | - | - | - | - | - | - | - | 2 |
| Upstate Carolina Consortium NCORP | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Vanderbilt U - Ingram CC LAPS | - | 1 | 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Virginia Mason Med Ctr | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | 2 |
| Western States Ca Res NCORP | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Wisconsin NCORP | - | 4 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | 3 | 1 | 1 | - | - | - | 8 | - | - | - | - | - | - | - | 1 |
| ALLIANCE | 110 | 72 | 12 | - | - | - | - | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | 111 | 51 | 22 | - | - | - | - | - | - | - | - | - | - | - | - |
| NRG | 88 | 54 | 68 | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | 1,000 | 497 | 233 | 16 | 4 | 11 | 93 | 8 | 20 | 78 | 4 | 17 | 3 | 8 | 174 |

Genitourinary Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | EA8153 | EA8171 | EA8183 | EA8191 | NRGGU002 | NRGGU005 | NRGGU008 | NRGGY023 |
|---------------------------------------|--------|--------|--------|--------|----------|----------|----------|----------|
| Ascension Prov Hospitals - Southfield | - | - | - | - | - | - | - | - |
| Banner MD Anderson CC | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | - | - | - | - | - | - | - | - |
| Baylor Coll Med/Dan L Duncan CCC | - | - | - | - | - | - | - | - |
| CWRU Case CCC LAPS | - | - | - | - | - | - | - | - |
| Ca Res Consortium West Mich NCORP | - | - | - | - | - | - | - | - |
| Ca Res for the Ozarks NCORP | - | - | - | - | - | - | - | - |
| Ca Res of Wisconsin & N Mich Consort | - | - | - | - | - | - | - | - |
| Cedars-Sinai Med Ctr | - | - | - | - | - | - | - | - |
| City of Hope CCC | - | - | - | - | - | - | - | - |
| Columbia U MU NCORP | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | - | - | - | - | - | - | - | - |
| Cotton O'Neil CC / Stormont Vail Hlth | - | - | - | - | - | - | - | - |
| Dayton NCORP | - | - | - | - | - | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | - | - | - | - | - | - | - | - |
| Georgia Cares MU NCORP | - | - | - | - | - | - | - | - |
| Gulf South MU NCORP | - | 11 | - | - | 1 | 1 | 3 | - |
| Hawaii MU NCORP | - | 1 | - | - | - | - | - | - |
| Heartland Ca Res NCORP | - | - | - | - | - | - | - | - |
| Henry Ford Hospital | - | - | - | - | - | - | - | - |
| Houston Methodist Hospital | - | - | - | - | - | - | - | - |
| Kaiser Permanente NCORP | 10 | - | - | - | - | - | - | - |
| Lahey Hospital & Med Ctr | - | - | 1 | - | - | - | - | - |
| Loma Linda U Med Ctr | - | - | - | - | - | - | - | - |
| Loyola U Med Ctr | - | - | - | - | - | - | - | - |
| Massachusetts Veterans ERIC | - | - | - | - | - | - | - | - |
| Medical U South Carolina MU NCORP | - | - | - | - | - | - | - | - |
| Michigan Ca Res Consortium NCORP | - | - | - | - | - | - | - | - |
| Moffitt CC | - | - | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | - | - | - | - | - | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | - | - | - | - | - | - | - | - |
| Nevada Ca Res Foundation NCORP | - | - | - | - | - | - | - | - |
| New Mexico MU NCORP | - | - | - | - | - | 1 | - | - |
| Northwell Health NCORP | - | - | - | - | - | - | - | - |
| Northwestern U LAPS | - | - | - | - | - | - | - | - |
| Ohio State U CCC LAPS | - | - | - | - | - | - | - | - |

Genitourinary Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | EA8153 | EA8171 | EA8183 | EA8191 | NRGGU002 | NRGGU005 | NRGGU008 | NRGGY023 |
|---------------------------------------|-----------|-----------|----------|----------|----------|----------|----------|----------|
| Oregon Health & Science U | - | 2 | - | - | - | - | - | - |
| Pacific Ca Res Consortium NCORP | - | - | - | - | - | - | - | - |
| SCL Health Saint Joseph Hospital | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | - | - | - | - | - | - | - | - |
| Sutter Ca Res Consortium | - | - | - | - | - | 2 | - | 1 |
| Tulane U Health Sciences Ctr | - | - | - | - | - | 1 | - | - |
| UC Davis CCC LAPS | - | - | - | - | - | - | - | - |
| UC Irvine Health/Chao Family CCC | - | - | - | - | - | - | - | - |
| UC San Diego Moores CC | - | - | - | - | - | - | - | - |
| UCLA / Jonsson CCC | - | - | - | - | - | - | - | - |
| USC Norris CCC LAPS | - | - | - | - | - | - | - | - |
| U Alabama Birm/Deep South RC LAPS | - | - | - | - | - | - | - | - |
| U Arkansas for Medical Sciences | - | - | - | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | - | - | - | - | - | - | - |
| U Colorado CC LAPS | - | - | - | - | 1 | 1 | - | - |
| U Kansas CC - MCA Rural MU NCORP | 1 | - | - | - | - | - | - | - |
| U Kentucky/Markey CC | - | - | - | - | - | - | - | - |
| U Michigan CCC LAPS | - | - | - | - | - | - | - | - |
| U Mississippi Med Ctr | 2 | - | - | - | 1 | - | - | - |
| U Oklahoma Health Sciences Ctr LAPS | - | - | - | 1 | - | - | - | - |
| U Rochester LAPS | - | - | - | - | - | - | - | - |
| U Texas HSC at San Antonio | - | 45 | - | - | - | - | - | - |
| U Texas MD Anderson CC LAPS | 8 | - | - | - | - | - | - | - |
| U Utah - Huntsman Ca Inst LAPS | 8 | - | - | - | - | - | - | - |
| Upstate Carolina Consortium NCORP | - | - | - | - | - | - | - | - |
| Vanderbilt U - Ingram CC LAPS | - | - | - | - | - | - | - | - |
| Virginia Mason Med Ctr | - | - | - | - | - | 3 | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | - | - | - | 1 | - | - | - |
| Western States Ca Res NCORP | - | - | - | - | - | - | - | - |
| Wisconsin NCORP | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | 2 | - | - | - | - | - | - | - |
| ALLIANCE | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | - | - | - | - | - | - | - | - |
| NRG | - | - | - | - | - | - | - | - |
| Total | 31 | 59 | 1 | 1 | 4 | 9 | 3 | 1 |

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
Vice-Chair: Anjali S. Advani, MD
Executive Officer: Susan M. O'Brien, MD
Statisticians: Megan Othus, PhD
..... Anna Moseley, MS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
Pathology: David R. Head, MD
Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
Data Coordinators: Louise Highleyman
..... Tracy Maher, CCRP
..... Laura Kingsbury
Oncology Research Professionals:
CRA: TBD
Nurse: Kristine D. Abueg, RN, MSN
Patient Advocate: Gail Sperling, MPH
Pharmaceutical Science: Holly O. Chan, PharmD
..... Ila M. Saunders, PharmD
Protocol Project Manager: Sharon Palmer
Protocol Project Manager - MyeloMATCH: Sarah Cantu
Clinical Trials Program Manager: TBD

Time/Location

Saturday, April 9, 2022 8:15 - 10:15 am
VIRTUAL ONLY

Agenda

AML/MDS Studies

Active Studies

CTSU/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19.

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Closed: 9/1/20.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15.

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutic(s)" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older." Drs. Michaelis and Walter. Activated: 12/22/17; Closed: 10/22/18.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

S1318, "A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. Advani, O'Dwyer, and Wood. Activated: 1/12/15; Permanent Closure of Cohort 1: 9/15/17; Permanent Closure of Steps 1 and 2: 4/15/21.

CTSU/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17.

Proposed Studies

S2113, "A Randomized Phase II Trial to Evaluate the Efficacy of Combination Bcl-2 Inhibitor Therapy with Chemotherapy Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma." Dr. K. O'Dwyer.

Leukemia Committee

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/01/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 4/15/21.

CLL Studies

Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

CTSU/A041702, "A Randomized Phase III Study of Ibrutinib Plus

Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19.

Closed Studies

CTSU/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CML Studies

Active Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18.

MyeloMATCH

Proposed Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Trials." Dr. J. Radich.

MM1YA-S01, "A Randomized Phase II Study of Novel Therapeutics in Younger Patients with High-Risk Acute Myeloid Leukemia." Dr. P. Shami.

MM10A-S02, "A Phase 2 Study of Targeted Agents with the Oral DNMT1 Inhibitor C-DEC (ASTX727) for the Treatment of TP53-Mutated Acute Myeloid Leukemia: A myeloMATCH treatment trial." Dr. R. Shallis.

Leukemia Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1318 | S1712 | S1905 | S1925 | A041501 | A041701 | A041702 | A041703 | EA9161 | EA9171 | EA9181 |
|---|-------|-------|-------|-------|---------|---------|---------|---------|--------|--------|--------|
| Ascension Via Christi Hospitals Wichita | 1 | - | - | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | - | - | - | - | - | - | 4 | - | 4 | - | - |
| Baptist Mem HC/Mid South MU NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| CWRU Case CCC LAPS | 6 | - | 1 | 1 | 4 | - | 3 | - | - | - | - |
| Ca Res for the Ozarks NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| City of Hope CCC | 4 | - | 1 | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | - | - | - | - | - | - | - | - | 1 | - | - |
| Dayton NCORP | - | - | - | - | - | - | 1 | - | 2 | - | - |
| Duke U - Duke Ca Inst LAPS | - | 3 | - | - | - | - | - | - | 9 | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | - | 1 | 1 | - | - | - | - | - | 9 | - | - |
| Hawaii MU NCORP | - | 6 | - | - | - | - | - | - | - | - | 1 |
| Heartland Ca Res NCORP | 1 | 4 | - | - | - | - | - | - | - | - | - |
| Henry Ford Hospital | - | - | - | 1 | - | 4 | 3 | - | 1 | - | - |
| Intermountain Med Ctr | - | - | - | - | 2 | - | - | - | - | - | - |
| Kaiser Permanente NCORP | - | - | - | - | - | - | 6 | - | 32 | - | - |
| Lahey Hospital & Med Ctr | - | - | - | - | - | - | 1 | - | - | - | - |
| Loma Linda U Med Ctr | 1 | - | - | - | - | - | - | - | - | - | - |
| Loyola U Med Ctr | - | 1 | - | - | - | - | 1 | - | 2 | - | - |
| Medical U South Carolina MU NCORP | - | - | - | 1 | - | - | 1 | - | 7 | - | - |
| Michigan Ca Res Consortium NCORP | - | 1 | - | 1 | - | - | - | - | - | - | - |
| Moffitt CC | - | 11 | - | - | - | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | 1 | 1 | - | - | - | - | - | - | 1 | - | - |
| Nevada Ca Res Foundation NCORP | - | 1 | - | - | - | - | 3 | - | 5 | - | - |
| New Mexico MU NCORP | 1 | 3 | - | - | - | - | - | - | 1 | - | - |
| Northwell Health NCORP | - | - | - | - | - | 2 | - | - | - | - | - |

Leukemia Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1318 | S1712 | S1905 | S1925 | A041501 | A041701 | A041702 | A041703 | EA9161 | EA9171 | EA9181 |
|---------------------------------------|-----------|-----------|----------|-----------|-----------|-----------|-----------|----------|------------|----------|-----------|
| Northwestern U LAPS | - | - | - | - | 1 | 1 | 2 | - | - | - | 3 |
| Oregon Health & Science U | - | 3 | 1 | - | 7 | - | 4 | - | 9 | - | - |
| Orlando Health Ca Inst | 1 | - | - | - | - | - | - | - | - | - | - |
| Salem Hospital | - | - | - | - | - | - | - | - | 4 | - | - |
| Southeast Clin Onc Res Consort NCORP | - | - | - | - | - | - | - | - | 2 | - | - |
| Stanford Ca Inst Palo Alto | - | - | - | - | 8 | - | 11 | - | 29 | - | - |
| UC Davis CCC LAPS | - | - | - | - | 2 | - | - | - | - | - | - |
| UC Irvine Health/Chao Family CCC | 4 | - | - | - | 3 | - | - | - | - | - | - |
| UC San Diego Moores CC | 1 | - | - | - | - | - | - | - | - | - | - |
| USC Norris CCC LAPS | 3 | - | - | - | - | - | - | - | - | - | - |
| U Alabama Birm/Deep South RC LAPS | 1 | - | - | - | 1 | - | - | - | 7 | - | - |
| U Arkansas for Medical Sciences | - | - | - | - | - | 4 | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | - | 1 | - | - | - | - | 1 | - | - | 1 |
| U Colorado CC LAPS | - | - | - | - | - | - | 1 | - | 1 | - | - |
| U Kansas CC - MCA Rural MU NCORP | - | - | - | - | - | - | 6 | - | 8 | - | - |
| U Michigan CCC LAPS | 2 | - | - | - | - | - | - | - | - | - | - |
| U Rochester LAPS | 4 | 5 | 1 | 2 | 5 | 27 | 1 | 3 | 1 | - | 5 |
| U Utah - Huntsman Ca Inst LAPS | - | 5 | - | 4 | 1 | - | 4 | - | 22 | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | - | - | - | - | - | - | - | 4 | - | 2 |
| Western States Ca Res NCORP | - | - | - | - | - | - | 2 | - | 1 | - | - |
| Yale U - Yale CC LAPS | 1 | - | - | - | 4 | - | 2 | - | 10 | 2 | - |
| ALLIANCE | 17 | 9 | 2 | 1 | - | - | - | - | - | - | - |
| ECOG-ACRIN | 6 | 5 | - | 2 | - | - | - | - | - | - | - |
| NRG | 2 | 2 | - | - | - | - | - | - | - | - | - |
| Total | 57 | 64 | 8 | 13 | 38 | 38 | 56 | 4 | 172 | 2 | 12 |

Lung Committee

Leadership

Chair: Jhanelle Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Katherine Minichiello, MS
 Jieling Miao, MS
 James Moon, MS
 Lu Qian, MS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Roy H. Decker, MD, PhD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Roy H. Decker, MD, PhD
 Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Cheryl M. Czerlanis, MD
 Data Coordinators: Leah Everhart
 Louise Highleyman
 Larry Kaye
 Amy Johnson
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRAs: Courtney L. Williamson
 Ginny M. Keeling, MS
 Nurses: Kimberly M. Belzer, MS, PAC
 Rosalie Zablocki, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Kimberly McConnell, PharmD

Protocol Project Managers: Mariah Norman
 Laura Gildner, MS (Lung-MAP)
 Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Saturday, April 9, 2022 8:30 - 11:30 am
 Room: Columbia A, Level 3

Agenda

| | |
|------------------|---|
| 8:30 – 8:40 am | General Update |
| 8:40 – 8:50 am | Patient Advocate Update: Judy Johnson, MBA |
| 8:50 – 9:00 am | Thoracic Surgery Session: Wayne Hofstetter, MD |
| 9:00 – 9:10 am | Thoracic Radiation Session: Megan Daly, MD |
| 9:10 – 9:20 am | Translational Medicine Session: Phil C. Mack, PhD |
| 9:20 – 9:30 am | Community Engagement Core: Paul J. Hesketh, MD |
| 9:30 – 10:00 am | Scientific Presentation #1 Targeting myeloid lineage cells to improve ICB efficacy in NSCLC McGarry Houghton, MD Lung SPORE PI Professor, Clinical Research Division & Human Biology Division Fred Hutchinson Cancer Research Center |
| 10:00 – 11:00 am | Thoracic Medical Oncology Session: Jhanelle Gray, MD |
| 11:00 – 11:30 am | Scientific presentation #2 Immuno-oncology Biomarkers on Lung Cancer and the CIMAC-CIDC Network Ignacio I. Wistuba, MD Head ad <i>interim</i> , Division of Pathology and Laboratory Medicine Chair, Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center |

Active Studies

LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).” Drs. Herbst, Patel, Gandara, et al. Activation: 1/28/19.

S1800D, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small

Lung Committee

Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)." Drs. Padda and Gerber. Activation: 4/2/21.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial Of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of First-line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

CTSU/A081105, "Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Kelly. Activation: 8/18/14; Temporary closure: 6/15/20; Reactivation: 7/15/20. Closed to Accrual: 1/20/21.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for

Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20; Temporary closure: 10/22/21.

CTSU/A082002, "A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer." Dr. Armini. Activation: 12/21/21.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20.

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19.

Closed Studies

None since October 2021.

NCI-Approved Concepts

S1900F, "A Phase II Study of Selpercatinib, Carboplatin and Pemetrexed In Patients With RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Elamin and Gray.

Concepts in Development

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge.

S1900H, "A Phase II Study of Tepotinib and Ramucirumab in Participants with Met Exon 14 Skipping and Advanced Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le.

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | LUNGMAP | S1701 | S1800A | S1827 | S1900A | S1900B | S1900C | S1900E | S1914 | S1929 | S1933 | A081105 |
|---|---------|-------|--------|-------|--------|--------|--------|--------|-------|-------|-------|---------|
| Ascension Prov Hospitals - Southfield | 12 | - | - | - | - | - | - | - | - | 1 | - | - |
| Ascension Via Christi Hospitals Wichita | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Banner MD Anderson CC | - | - | - | - | - | - | - | - | - | - | - | - |
| Banner U Med Ctr - Tucson | - | - | - | - | - | - | - | - | - | - | - | - |
| Baptist Mem HC/Mid South MU NCORP | 34 | - | - | - | 3 | - | 1 | 1 | 2 | 2 | - | - |
| Boston Med Ctr | - | - | - | 3 | - | - | - | - | - | - | - | - |
| CWRU Case CCC LAPS | 5 | - | - | - | - | - | 1 | 1 | - | - | - | 6 |
| Ca Res Consortium West Mich NCORP | 3 | - | 1 | - | 1 | - | 1 | - | 2 | - | - | - |
| Ca Res for the Ozarks NCORP | 27 | - | - | - | - | - | 2 | - | - | 2 | 3 | 1 |
| Ca Res of Wisconsin & N Mich Consort | 18 | - | - | - | 2 | - | 2 | 3 | - | - | - | - |
| Carle CC NCORP | 2 | - | - | - | - | - | - | - | - | - | - | - |
| Cedars-Sinai Med Ctr | 2 | - | - | - | - | - | - | - | - | - | - | - |
| City of Hope CCC | 5 | 1 | - | 1 | - | - | - | - | - | - | - | 1 |
| Columbia U MU NCORP | 6 | - | - | - | 1 | - | 1 | - | - | - | - | - |
| Columbus NCORP | 21 | - | - | 2 | 4 | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | 43 | - | 6 | - | 1 | - | 1 | - | 1 | 2 | - | - |
| Cotton O'Neil CC / Stormont Vail Hlth | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Dayton NCORP | 6 | - | - | - | - | - | - | - | - | 1 | - | - |
| Essentia Health NCORP | 15 | - | - | - | - | - | 1 | - | 1 | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | 4 | - | - | - | - | - | - | - | - | - | - | 1 |
| Georgia Cares MU NCORP | 6 | - | 1 | 1 | - | - | - | - | 2 | 3 | 1 | - |
| Georgia NCORP | 45 | - | 3 | 2 | 2 | - | - | - | 1 | - | - | - |
| Gulf South MU NCORP | 7 | - | - | 1 | - | - | - | - | 1 | - | - | - |
| Hawaii MU NCORP | 21 | - | 1 | - | - | - | - | - | - | - | - | - |
| Heartland Ca Res NCORP | 102 | - | 11 | - | 6 | 1 | 1 | 4 | 13 | 10 | 1 | - |
| Henry Ford Hospital | 7 | - | - | - | 2 | - | - | - | - | 1 | - | 2 |
| Houston Methodist Hospital | - | - | - | - | - | - | - | - | - | - | - | 2 |
| Kaiser Permanente NCORP | 51 | - | 2 | - | - | - | 1 | 6 | 1 | - | - | 19 |
| Lahey Hospital & Med Ctr | 25 | - | 4 | - | - | - | - | - | 1 | 1 | 2 | - |
| Loma Linda U Med Ctr | 5 | - | - | - | - | - | 1 | - | - | - | - | 3 |
| Loyola U Med Ctr | 18 | - | 1 | - | - | - | - | - | - | - | - | - |
| Massachusetts Veterans ERIC | 28 | - | 4 | - | 1 | - | - | - | - | - | - | 1 |
| Medical U South Carolina MU NCORP | 7 | - | - | - | - | - | - | 1 | - | - | - | - |
| Michigan Ca Res Consortium NCORP | 84 | - | 10 | - | 3 | - | 5 | 4 | 1 | 1 | - | - |
| Moffitt CC | 5 | 2 | - | 1 | - | - | - | - | - | - | - | 3 |
| Montana Cancer Consortium NCORP | 24 | - | 5 | - | 2 | - | 1 | - | - | 3 | 1 | - |
| Mount Sinai Hospital | - | - | - | - | - | - | - | - | 6 | - | - | - |
| NCORP Carolinas (Prisma Hlth NCORP) | 15 | - | 1 | - | - | - | - | 1 | - | - | - | - |
| Nevada Ca Res Foundation NCORP | 11 | - | 1 | - | - | - | - | - | - | - | - | - |

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | LUNGMAP | S1701 | S1800A | S1827 | S1900A | S1900B | S1900C | S1900E | S1914 | S1929 | S1933 | A081105 |
|---------------------------------------|--------------|-----------|------------|-----------|-----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|
| New Mexico MU NCORP | 64 | - | 3 | 1 | 2 | - | - | - | 3 | 3 | 1 | - |
| Northwell Health NCORP | - | - | - | - | - | - | - | - | - | - | - | - |
| Northwestern U LAPS | 19 | 1 | - | - | - | - | - | - | - | 1 | - | - |
| Oregon Health & Science U | 1 | - | - | - | - | - | - | - | 1 | - | - | 1 |
| Pacific Ca Res Consortium NCORP | 12 | - | - | - | - | - | - | - | - | 3 | - | - |
| SCL Health Saint Joseph Hospital | 1 | - | - | - | - | - | - | - | 1 | - | - | - |
| Salem Hospital | 3 | - | 1 | - | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | 43 | - | 8 | 4 | 2 | - | - | - | 2 | 3 | - | - |
| Sutter Ca Res Consortium | 20 | - | 2 | - | - | - | - | 1 | - | - | - | 1 |
| Don & Sybil Harrington CC | 6 | - | - | - | - | - | - | - | - | - | - | - |
| James Graham Brown CC at U Louisville | - | - | - | - | - | - | - | - | - | - | - | - |
| UC Davis CCC LAPS | 20 | 3 | 3 | 1 | 3 | - | - | - | 4 | 1 | - | 4 |
| UC Irvine Health/Chao Family CCC | 17 | - | 1 | 1 | - | - | - | - | 1 | - | - | 2 |
| UC San Diego Moores CC | 9 | - | - | - | - | - | - | 1 | - | - | - | 1 |
| UPMC Hillman CC LAPS | 13 | - | - | - | - | - | - | 3 | - | - | - | - |
| USC Norris CCC LAPS | - | - | - | - | - | - | - | - | 1 | - | - | 1 |
| U Arkansas for Medical Sciences | 9 | - | 3 | - | - | - | - | - | 4 | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | - | - | - | - | - | - | - | - | - | - | 1 |
| U Colorado CC LAPS | 10 | - | 1 | 1 | - | - | - | - | 2 | 1 | - | 9 |
| U Kansas CC - MCA Rural MU NCORP | 72 | - | 4 | - | 4 | - | 2 | 1 | - | - | - | 1 |
| U Kentucky/Markey CC | 40 | - | 2 | 1 | - | - | 3 | - | - | - | - | 1 |
| U Michigan CCC LAPS | 1 | - | - | - | - | - | - | - | - | - | - | 1 |
| U Mississippi Med Ctr | 1 | - | 1 | - | - | - | - | - | - | - | - | 2 |
| U Oklahoma Health Sciences Ctr LAPS | 24 | - | 2 | 1 | 1 | - | - | - | - | - | 7 | - |
| U Rochester LAPS | 49 | - | 2 | - | 3 | - | - | 5 | 1 | - | - | - |
| U Texas HSC at San Antonio | - | - | - | - | - | - | - | - | - | - | - | - |
| U Texas MD Anderson CC LAPS | 3 | 4 | - | - | - | - | - | - | - | 2 | - | - |
| U Utah - Huntsman Ca Inst LAPS | - | - | - | 1 | - | - | - | - | 2 | - | - | - |
| Upstate Carolina Consortium NCORP | 23 | - | 5 | - | - | - | 1 | - | 1 | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Western States Ca Res NCORP | 2 | - | - | - | - | - | - | - | - | - | - | - |
| William Beaumont Hosp-Royal Oak | - | - | - | - | - | - | - | - | - | - | - | - |
| Wisconsin NCORP | 34 | - | 1 | - | 1 | - | 1 | - | 2 | - | - | - |
| Yale U - Yale CC LAPS | 16 | - | 7 | 1 | 1 | - | 3 | - | - | - | - | 3 |
| ALLIANCE | 562 | 3 | 36 | 9 | 9 | 1 | 9 | 6 | 4 | 3 | 1 | - |
| CCTG | - | - | - | 2 | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | 270 | 2 | 17 | 2 | 5 | 2 | 7 | 8 | 4 | 5 | - | - |
| NRG | 265 | - | 15 | 34 | 5 | 2 | 2 | 2 | 6 | 5 | 1 | - |
| Total | 2,275 | 16 | 166 | 70 | 64 | 6 | 47 | 48 | 71 | 54 | 18 | 67 |

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | A081801 | A151216 | E4512 | EA5163 | EA5181 | EA5182 | EA5191 | NRGCC003 | NRGLU002 | NRGLU005 | R1308 |
|---|---------|---------|-------|--------|--------|--------|--------|----------|----------|----------|-------|
| Ascension Prov Hospitals - Southfield | - | 14 | 1 | 2 | 1 | - | 1 | - | - | - | - |
| Ascension Via Christi Hospitals Wichita | - | - | - | - | - | - | - | - | - | - | - |
| Banner MD Anderson CC | 1 | 1 | - | - | - | - | - | - | - | 1 | - |
| Banner U Med Ctr - Tucson | - | 7 | 2 | - | 4 | - | - | - | - | - | - |
| Baptist Mem HC/Mid South MU NCORP | - | 19 | - | - | - | - | - | - | 1 | 3 | - |
| Boston Med Ctr | - | 3 | - | - | 1 | - | - | - | - | - | - |
| CWRU Case CCC LAPS | 4 | 48 | - | 7 | 10 | - | - | - | - | - | - |
| Ca Res Consortium West Mich NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| Ca Res for the Ozarks NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| Ca Res of Wisconsin & N Mich Consort | - | - | - | - | - | - | - | - | - | - | - |
| Carle CC NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Cedars-Sinai Med Ctr | - | - | - | - | - | - | - | - | - | - | - |
| City of Hope CCC | - | 4 | - | - | - | - | - | - | - | - | - |
| Columbia U MU NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Columbus NCORP | - | - | - | - | - | - | - | - | - | - | - |
| CommonSpirit Health Research Inst | - | 2 | - | - | - | - | - | - | - | - | - |
| Cotton O'Neil CC / Stormont Vail Hlth | - | 3 | - | - | - | - | - | - | - | - | - |
| Dayton NCORP | - | 8 | - | - | - | - | - | - | - | - | - |
| Essentia Health NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Fred Hutchinson Ca Res Ctr LAPS | - | 15 | - | - | - | - | - | - | - | - | - |
| Georgia Cares MU NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Georgia NCORP | - | 9 | - | 1 | - | - | - | - | - | - | - |
| Gulf South MU NCORP | - | - | - | 3 | - | - | - | - | - | - | - |
| Hawaii MU NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Heartland Ca Res NCORP | - | - | - | - | - | - | - | 1 | - | - | - |
| Henry Ford Hospital | 2 | 29 | - | - | - | - | - | - | - | - | - |
| Houston Methodist Hospital | - | 8 | - | - | - | - | - | - | - | - | - |
| Kaiser Permanente NCORP | 1 | 197 | 4 | 3 | - | 1 | - | - | - | - | - |
| Lahey Hospital & Med Ctr | - | 30 | - | 1 | - | - | - | - | - | - | - |
| Loma Linda U Med Ctr | - | 9 | - | - | - | - | - | - | - | - | 1 |
| Loyola U Med Ctr | - | 21 | - | - | 2 | - | - | - | - | - | - |
| Massachusetts Veterans ERIC | 6 | 25 | - | 3 | - | - | - | - | - | - | - |
| Medical U South Carolina MU NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Michigan Ca Res Consortium NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Moffitt CC | 5 | 83 | 1 | - | - | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Mount Sinai Hospital | - | - | - | - | 1 | - | - | - | - | 1 | - |
| NCORP Carolinas (Prisma Hlth NCORP) | - | 1 | - | - | - | - | - | - | - | - | - |
| Nevada Ca Res Foundation NCORP | - | - | - | - | - | - | - | - | - | - | - |

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | A081801 | A151216 | E4512 | EA5163 | EA5181 | EA5182 | EA5191 | NRGCC003 | NRGLU002 | NRGLU005 | R1308 |
|---------------------------------------|-----------|------------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|
| New Mexico MU NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Northwell Health NCORP | 1 | 1 | - | - | - | - | - | - | - | - | - |
| Northwestern U LAPS | - | - | - | - | - | - | - | - | - | - | - |
| Oregon Health & Science U | 4 | 19 | - | - | - | - | - | - | - | - | - |
| Pacific Ca Res Consortium NCORP | - | 4 | - | - | - | - | - | - | - | - | - |
| SCL Health Saint Joseph Hospital | 1 | 2 | - | - | - | - | - | - | - | - | - |
| Salem Hospital | - | - | - | - | - | - | - | - | - | - | - |
| Southeast Clin Onc Res Consort NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Sutter Ca Res Consortium | - | 10 | - | - | 2 | - | - | - | - | - | - |
| Don & Sybil Harrington CC | - | - | - | - | - | - | - | - | - | - | - |
| James Graham Brown CC at U Louisville | - | 5 | - | - | - | - | - | - | - | - | - |
| UC Davis CCC LAPS | - | 41 | 1 | 6 | - | 1 | - | - | - | - | - |
| UC Irvine Health/Chao Family CCC | - | 12 | - | - | - | - | - | - | - | - | - |
| UC San Diego Moores CC | - | 5 | - | - | - | - | - | - | - | - | - |
| UPMC Hillman CC LAPS | - | - | - | - | - | - | - | - | - | - | - |
| USC Norris CCC LAPS | - | 12 | - | - | - | - | - | - | - | - | - |
| U Arkansas for Medical Sciences | - | 2 | - | 1 | - | - | - | - | - | - | - |
| U Cincinnati CC-UC Med Ctr | - | 22 | 1 | - | - | - | - | - | - | - | - |
| U Colorado CC LAPS | 3 | 58 | 2 | - | - | - | 1 | - | - | 1 | - |
| U Kansas CC - MCA Rural MU NCORP | - | 28 | - | 3 | - | - | - | - | - | 2 | - |
| U Kentucky/Markey CC | - | 5 | - | - | - | - | - | - | - | - | - |
| U Michigan CCC LAPS | - | 62 | - | - | - | - | - | - | - | - | - |
| U Mississippi Med Ctr | - | 26 | - | - | - | - | - | - | - | - | - |
| U Oklahoma Health Sciences Ctr LAPS | - | - | - | - | - | - | - | - | - | - | - |
| U Rochester LAPS | - | - | - | 2 | 9 | - | - | 4 | - | 1 | - |
| U Texas HSC at San Antonio | - | - | - | 2 | - | - | - | - | - | - | - |
| U Texas MD Anderson CC LAPS | - | 2 | 1 | - | - | - | - | - | - | - | - |
| U Utah - Huntsman Ca Inst LAPS | - | - | - | 1 | - | - | - | - | - | - | - |
| Upstate Carolina Consortium NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Wayne State U - Karmanos Ca Inst LAPS | - | 1 | - | - | - | - | - | - | 1 | - | - |
| Western States Ca Res NCORP | - | 1 | - | - | - | - | - | - | - | - | - |
| William Beaumont Hosp-Royal Oak | - | 2 | - | - | - | - | - | - | - | - | - |
| Wisconsin NCORP | - | - | - | - | - | - | - | - | - | - | - |
| Yale U - Yale CC LAPS | 3 | 51 | 4 | 10 | - | - | - | - | - | - | - |
| ALLIANCE | - | - | - | - | - | - | - | - | - | - | - |
| CCTG | - | - | - | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | - | - | - | - | - | - | - | - | - | - | - |
| NRG | - | - | - | - | - | - | - | - | - | - | - |
| Total | 31 | 909 | 17 | 45 | 30 | 2 | 2 | 5 | 2 | 9 | 1 |

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
Vice-Chair: Sonali M. Smith, MD
Executive Officer: Susan M. O'Brien, MD
Statisticians: Michael LeBlanc, PhD
..... Hongli Li, MS

Scientific Leadership

Translational Medicine: Alexey V. Danilov, MD, PhD
Radiation Oncology: Louis S. Constine, MD
Imaging: Lawrence H. Schwartz, MD
Pathology: Joo Y. Song, MD
Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
Digital Engagement: Mazyar Shadman, MD
Veterans Affairs: Helen Ma, MD
Data Coordinators: Iris Syquia
..... Gabi Herbert

Oncology Research Professionals:

CRA: Erin M. Cebula, MPH
Nurse: Molly Beth Adamek, BSN, RN
Patient Advocate: Hildy Dillon, MPH
Pharmaceutical Science: Holly O. Chan, PharmD
..... Martina Fraga, PharmD
Protocol Project Manager: Alicia Aranda
Clinical Trials Program Manager: Michelle Maxim

Time/Location

Friday, April 8, 2022 9:00 am - 12:00 pm
Room: Quinalt, Level 5

Agenda

9:00 am: Welcome - Drs. Jonathan Friedberg and Sonali Smith

9:05 - 9:50 am: **Mini-symposium: Novel diagnostic and therapeutic approaches to B-cell malignancies**

Ultrasensitive Duplex Sequencing for Applications in Hematologic Malignancies

Jesse Salk MD, PhD

CEO, CSO, Founder

TwinStrand Biosciences Inc.

Clinical Assistant Professor

University of Washington, Division of Medical Oncology

Targeting CD20 with novel CAR-T constructs

Brian Till, MD

Associate Professor

University of Washington, Division of Medical Oncology

Fred Hutchinson Cancer Research Center

9:50 - 10:30 am: New Concepts

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Re-lapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Dr. Hess.

S2207, "Randomized phase II study of the addition of COO (cell-of-origin)-directed therapeutic agents to ta-fasitamab-based therapy in non-transplant-eligible patients with relapsed/refractory diffuse large B-cell lymphoma." Drs. Persky, Amengual and Reagan

Alliance Mantle Cell lymphoma - Dr. Phillips

COG Early stage Hodgkin lymphoma - Dr. Hu

10:30 - 10:50 am: ASH Review - New treatment approaches to newly diagnosed and relapsed diffuse large B-cell lymphoma - Dr. Kamdar

10:50 - 11:50 am: Ongoing Studies

S1826: Dr. Herrera

S1918: Dr. Brem

S1608: Dr. Barr

A051301: Dr. Stiff

A051902: Dr. Amengual

ANHL1931: Dr. Kamdar

EA4151: Dr. Till

E4412: Dr. Amengual

EA4181: Dr. Spurgeon

A051701: Dr. Vallurupalli

S1925 (CLL): Dr. Stephens

11:50 am - 12:00 pm: Other Business/Concluding Remarks

Lymphoma Committee

Active Studies

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera and Friedberg. Activated: 7/19/19.

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Temporarily Closed as of 02/09/22

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

CTSU/A051301, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Drs. Andreadis, Fenske, Leonard, Devine, Shea, Hsi, Kelley, and Richards. SWOG Champion: Dr. Stiff. Activated: 7/6/16.

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Drs. Fenske, Till, Blum, Lazarus, Scott, and Kostakoglu. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma. Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." SWOG Champion: Dr. Kamdar. SWOG Champion: Dr. Manali. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Neha Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

Open Leukemia Studies

S1925, A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study. Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Re-lapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Veneto-clax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Woyach. SWOG Champion: Dr. Hill. Activated: 1/4/19.

Open Rare Cancers Study

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Drs. Chen, Flaherty, Conley, et al. Activated: 8/12/15.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/27/2021.

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1608 | S1826 | S1918 | A051301 | A051701 | E4412 | EA4151 | EA4181 |
|---|-------|-------|-------|---------|---------|-------|--------|--------|
| Ascension Providence Hospitals - Southfield | - | 5 | - | - | - | - | - | - |
| Banner University Medical Center - Tucson | 2 | - | - | 1 | - | - | 1 | 2 |
| Baptist Memorial Health Care/Mid South Minority Underserved NCORP | - | 2 | - | - | - | - | - | - |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | - | - | - | 1 | - | - | - | - |
| Boston Medical Center | - | 2 | - | - | - | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - | 8 | - | 8 | 10 |
| Cancer Research Consortium of West Michigan NCORP | 3 | 8 | - | - | - | - | - | - |
| Cancer Research for the Ozarks NCORP | 1 | 4 | - | - | - | - | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | 1 | - | - | - | - | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | 1 | - | - | - | - | - | - | - |
| City of Hope Comprehensive Cancer Center | 8 | 15 | - | 1 | - | - | 15 | - |
| Columbia University Minority Underserved NCORP | - | 1 | 2 | - | - | 1 | - | - |
| Columbus NCI Community Oncology Research Program | 1 | 2 | - | - | - | - | - | - |
| CommonSpirit Health Research Institute | - | 3 | - | - | - | - | - | - |
| Essentia Health NCI Community Oncology Research Program | - | 1 | - | - | - | - | - | - |
| Fred Hutchinson Cancer Research Center LAPS | - | - | - | - | - | - | 11 | - |
| Georgia Cares Minority Underserved NCORP | - | 2 | 1 | - | - | - | - | - |
| Gulf South Minority Underserved NCORP | - | - | 1 | - | - | - | - | - |
| Heartland Cancer Research NCORP | 1 | 16 | - | - | - | - | - | - |
| Henry Ford Hospital | - | 6 | - | - | 2 | - | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | 2 | 10 | - | - | - | 11 | - | 5 |
| King Faisal Specialist Hospital and Research Centre | - | - | - | 4 | - | - | - | - |
| Loyola University Medical Center | - | 5 | - | - | - | - | 3 | - |
| Medical University of South Carolina Minority Underserved NCORP | 2 | 13 | - | - | 3 | - | 2 | - |
| Michigan Cancer Research Consortium NCORP | 1 | 2 | - | - | - | - | - | - |
| Moffitt Cancer Center | - | 13 | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | - | 8 | - | - | - | - | - | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | 10 | - | - | - | - | 2 | - |

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1608 | S1826 | S1918 | A051301 | A051701 | E4412 | EA4151 | EA4181 |
|---|-----------|------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Nevada Cancer Research Foundation NCORP | - | 1 | - | - | - | 1 | - | - |
| Northwell Health NCORP | - | - | - | - | 1 | - | - | - |
| Northwestern University LAPS | 1 | - | - | - | - | - | - | - |
| Oregon Health and Science University | - | 2 | - | - | 2 | - | 4 | 5 |
| Pacific Cancer Research Consortium NCORP | - | 3 | - | - | - | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | 4 | - | - | - | - | - | - |
| UC Davis Comprehensive Cancer Center LAPS | - | 8 | - | - | 4 | - | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | 4 | - | - | - | - | - | - |
| UC San Diego Moores Cancer Center | - | 7 | - | - | - | - | 1 | - |
| University of Alabama at Birmingham / Deep South Research Consortium LAPS | - | 11 | - | - | 3 | 7 | 5 | - |
| University of Arkansas for Medical Sciences | - | 1 | - | - | - | - | - | - |
| University of Cincinnati Cancer Center-UC Medical Center | - | 6 | - | - | - | - | 1 | 1 |
| University of Colorado Cancer Center LAPS | - | 2 | - | 1 | - | - | - | - |
| University of Kentucky/Markey Cancer Center | - | 2 | - | - | - | - | - | - |
| University of Michigan Comprehensive Cancer Center LAPS | - | - | - | - | - | - | 1 | - |
| University of Rochester LAPS | 13 | 27 | - | 3 | 11 | - | 8 | 14 |
| University of Texas Health Science Center at San Antonio | - | 8 | - | - | - | - | 9 | - |
| University of Texas MD Anderson Cancer Center LAPS | 3 | 14 | - | - | - | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 1 | 12 | - | - | - | - | 12 | 10 |
| Upstate Carolina Consortium Community Oncology Research Program | 1 | 6 | - | - | - | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | 3 | - | 1 | - | - | 1 | 4 |
| Wisconsin NCI Community Oncology Research Program | - | 6 | - | - | - | - | - | - |
| Yale University - Yale Cancer Center LAPS | - | 4 | - | - | - | - | 2 | - |
| ALLIANCE | 15 | 85 | 9 | - | - | - | - | - |
| CCTG | - | 2 | - | - | - | - | - | - |
| COG | - | 227 | - | - | - | - | - | - |
| ECOG-ACRIN | 5 | 57 | 4 | - | - | - | - | - |
| NRG | 11 | 38 | 2 | - | - | - | - | - |
| Total | 72 | 669 | 19 | 12 | 34 | 20 | 86 | 51 |

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1608 | S1826 | S1918 | A051301 | A051701 | EA412 | EA4151 | EA4181 |
|---|-------|-------|-------|---------|---------|-------|--------|--------|
| Ascension Providence Hospitals - Southfield | - | 5 | - | - | - | - | - | - |
| Banner University Medical Center - Tucson | 2 | - | - | 1 | - | - | 1 | 2 |
| Baptist Memorial Health Care/Mid South Minority Underserved NCORP | - | 2 | - | - | - | - | - | - |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | - | - | - | 1 | - | - | - | - |
| Boston Medical Center | - | 2 | - | - | - | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - | 8 | - | 8 | 10 |
| Cancer Research Consortium of West Michigan NCORP | 3 | 8 | - | - | - | - | - | - |
| Cancer Research for the Ozarks NCORP | 1 | 4 | - | - | - | - | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | 1 | - | - | - | - | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | 1 | - | - | - | - | - | - | - |
| City of Hope Comprehensive Cancer Center | 8 | 15 | - | 1 | - | - | 15 | - |
| Columbia University Minority Underserved NCORP | - | 1 | 2 | - | - | 1 | - | - |
| Columbus NCI Community Oncology Research Program | 1 | 2 | - | - | - | - | - | - |
| CommonSpirit Health Research Institute | - | 3 | - | - | - | - | - | - |
| Essentia Health NCI Community Oncology Research Program | - | 1 | - | - | - | - | - | - |
| Fred Hutchinson Cancer Research Center LAPS | - | - | - | - | - | - | 11 | - |
| Georgia Cares Minority Underserved NCORP | - | 2 | 1 | - | - | - | - | - |
| Gulf South Minority Underserved NCORP | - | - | 1 | - | - | - | - | - |
| Heartland Cancer Research NCORP | 1 | 16 | - | - | - | - | - | - |
| Henry Ford Hospital | - | 6 | - | - | 2 | - | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | 2 | 10 | - | - | - | 11 | - | 5 |
| King Faisal Specialist Hospital and Research Centre | - | - | - | 4 | - | - | - | - |
| Loyola University Medical Center | - | 5 | - | - | - | - | 3 | - |
| Medical University of South Carolina Minority Underserved NCORP | 2 | 13 | - | - | 3 | - | 2 | - |
| Michigan Cancer Research Consortium NCORP | 1 | 2 | - | - | - | - | - | - |
| Moffitt Cancer Center | - | 13 | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | - | 8 | - | - | - | - | - | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | 10 | - | - | - | - | 2 | - |

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1608 | S1826 | S1918 | A051301 | A051701 | E4412 | EA4151 | EA4181 |
|---|-----------|------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Nevada Cancer Research Foundation NCORP | - | 1 | - | - | - | 1 | - | - |
| Northwell Health NCORP | - | - | - | - | 1 | - | - | - |
| Northwestern University LAPS | 1 | - | - | - | - | - | - | - |
| Oregon Health and Science University | - | 2 | - | - | 2 | - | 4 | 5 |
| Pacific Cancer Research Consortium NCORP | - | 3 | - | - | - | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | 4 | - | - | - | - | - | - |
| UC Davis Comprehensive Cancer Center LAPS | - | 8 | - | - | 4 | - | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | 4 | - | - | - | - | - | - |
| UC San Diego Moores Cancer Center | - | 7 | - | - | - | - | 1 | - |
| University of Alabama at Birmingham / Deep South Research Consortium LAPS | - | 11 | - | - | 3 | 7 | 5 | - |
| University of Arkansas for Medical Sciences | - | 1 | - | - | - | - | - | - |
| University of Cincinnati Cancer Center-UC Medical Center | - | 6 | - | - | - | - | 1 | 1 |
| University of Colorado Cancer Center LAPS | - | 2 | - | 1 | - | - | - | - |
| University of Kentucky/Markey Cancer Center | - | 2 | - | - | - | - | - | - |
| University of Michigan Comprehensive Cancer Center LAPS | - | - | - | - | - | - | 1 | - |
| University of Rochester LAPS | 13 | 27 | - | 3 | 11 | - | 8 | 14 |
| University of Texas Health Science Center at San Antonio | - | 8 | - | - | - | - | 9 | - |
| University of Texas MD Anderson Cancer Center LAPS | 3 | 14 | - | - | - | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 1 | 12 | - | - | - | - | 12 | 10 |
| Upstate Carolina Consortium Community Oncology Research Program | 1 | 6 | - | - | - | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | 3 | - | 1 | - | - | 1 | 4 |
| Wisconsin NCI Community Oncology Research Program | - | 6 | - | - | - | - | - | - |
| Yale University - Yale Cancer Center LAPS | - | 4 | - | - | - | - | 2 | - |
| ALLIANCE | 15 | 85 | 9 | - | - | - | - | - |
| CCTG | - | 2 | - | - | - | - | - | - |
| COG | - | 227 | - | - | - | - | - | - |
| ECOG-ACRIN | 5 | 57 | 4 | - | - | - | - | - |
| NRG | 11 | 38 | 2 | - | - | - | - | - |
| Total | 72 | 669 | 19 | 12 | 34 | 20 | 86 | 51 |

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
Vice-Chair: Roger S. Lo, MD, PhD
Executive Officer: Christopher W. Ryan, MD
Statisticians: Michael Wu, PhD
..... Megan Othus, PhD
..... James Moon, MS
..... Hongli Li, MS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
Radiation Oncology: Evan J. Wuthrick, MD
Surgery: John Robert Hyngstrom, MD
Dermatology: Clara Curiel-Lewandrowski, MD
Imaging: Ari M. VanderWalde, MD
Medical Oncology: Sapna Pradyuman Patel, MD
Pathology: TBD
Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
Early Therapeutics: Jeffrey A. Sosman, MD
SWOG's ECOG Liaisons: Thach-Giao Truong, MD
ECOG's SWOG Liaisons: David H. Lawson, MD
..... Andrew Poklepovic, MD
Digital Engagement: Zeynep Eroglu, MD

Designates

Cancer Control Liaison: Sancy Leachman, MD, PhD
..... Thach-Giao Truong, MD (Survivorship)
Data Coordinator: Tonya Johnson
..... Laura Kingsbury, MRT
..... Leah Everhart
..... Hannah Hale
Oncology Research Professionals:
CRA: Kathryn Allen, BA, CCRP
Nurse: Lisa S. Morgan, RN, OCN
Patient Advocate: Samantha Guild, JD
Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
..... Kimberly McConnell, PharmD
Protocol Project Manager: Catrina De Los Santos-Mireles
Clinical Trials Program Manager: Michelle Maxim

Time/Location

Friday, April 8, 2022 2:30 - 4:30 pm
Room: Quinalt, Level 5

Agenda

Welcome and Introduction: Sapna Patel, M.D. (10 min)

Keynote Speaker: The Role of the Oncology Community in Addressing Financial Hardships from Cancer Care - Veena Shankaran, M.D., Fred Hutchinson Cancer Research Center, co-director Hutchinson Institute for Cancer Outcomes Research (HICOR) (40 min)

Active Studies Update (15 min, 5 min ea) – Study design, eligibility criteria, endpoints, accrual to date

S2015, A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm vs. 2cm Wide Excision Margins for Primary Cutaneous Melanoma, MASC. PI: Joshua Mammen, M.D., Ph.D. (University of Nebraska)

S2000, A Randomized Phase II Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Braf-V600 Mutant Melanoma With Brain Metastases. PI: Zeynep Eroglu, M.D. (Moffit) Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.

S1801, A Phase II Randomized Study of Adjuvant Versus Neo-Adjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-risk Melanoma. Sapna Patel (MDACC). Activated PI: Sapna Patel, M.D. (MD Anderson) Biostatisticians: Megan Othus, Ph.D. & James Moon, M.S.

Closed to Patient Accrual (30 min), TM Updates

S1616, A Phase II Study of Ipilimumab and Nivolumab in Advanced Melanoma Following Progression on a PD-1 Inhibitor Alone. PI: Ari VanderWalde, M.D., M.P.H. (West Cancer Clinic). Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.

S1607, A Phase II Study of Combining T-VEC and PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy. PI: Siwen Hu-Lieskovan, M.D., Ph.D. (Huntsman Cancer Institute). Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.

S1512, A Study of PD-1 Blockade with Pembrolizumab In Patients with Primary Desmoplastic Melanoma (DM), Locally Advanced, Locally Recurrent, or Metastatic Desmoplastic Melanoma (DM). PI: Kari Kendra, M.D. (Ohio State) and Siwen Hu-Lieskovan, M.D., Ph.D. (Huntsman Cancer Institute). Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.

S1404, A Phase III Randomized Study of MK3475 versus High-Dose Interferon alfa-2b for Resected High-Risk Melanoma. PI: Sapna Patel, M.D. (MD Anderson). Biostatisticians: Megan Othus, Ph.D., James Moon, M.S., & Hongli Li, M.S.

Melanoma Committee

S1320, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma. PI: Alain Algazi, M.D. (University of California San Francisco). Biostatisticians: Megan Othus, Ph.D., James Moon, M.S.

S1221, Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer. PI: Alain Algazi, M.D. (University of California San Francisco) and Antoni Ribas (UCLA). Biostatisticians: Megan Othus, Ph.D. & James Moon, M.S.

ECOG / ALLIANCE Updates: David Lawson, M.D. (10 min)

Advocacy: Remarks (Samantha Guild, J.D., AIM at Melanoma)

Closing Remarks

Active Studies

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 9/23/20.

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/6/18.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/1/18.

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 9/10/15.

Closed Studies

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 6/4/21.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/17. Closed: 7/15/20.

CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

Studies in Development

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen.

Melanoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1512 | S1607 | S1616 | S1801 | S2000 |
|---|-------|-------|-------|-------|-------|
| Banner University Medical Center - Tucson | - | - | - | 7 | - |
| Boston Medical Center | - | - | - | 1 | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - | - | - | - |
| Cancer Research Consortium of West Michigan NCORP | - | - | 4 | 20 | - |
| Cancer Research for the Ozarks NCORP | - | - | - | - | 1 |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | - | 1 | 2 | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | - | - | 1 | 1 |
| City of Hope Comprehensive Cancer Center | - | - | 4 | 6 | - |
| Columbus NCI Community Oncology Research Program | - | - | - | 1 | - |
| Dayton NCI Community Oncology Research Program | - | - | 1 | - | - |
| Georgia NCI Community Oncology Research Program | 1 | - | - | - | - |
| Hawaii Minority Underserved NCORP | - | - | - | 2 | - |
| Heartland Cancer Research NCORP | - | - | - | 5 | - |
| Henry Ford Hospital | - | 4 | - | - | - |
| Intermountain Medical Center | 1 | - | - | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | - | - | 5 | 13 | - |
| Loma Linda University Medical Center | - | - | - | 2 | - |
| Massachusetts Veterans Epidemiology Research and Information Center | - | - | - | 5 | - |
| Medical University of South Carolina Minority Underserved NCORP | - | - | - | 1 | - |
| Michigan Cancer Research Consortium NCORP | - | - | - | 4 | - |
| Moffitt Cancer Center | 19 | - | 8 | - | 3 |
| Montana Cancer Consortium NCORP | - | - | 1 | 4 | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | - | - | - | - |
| Nevada Cancer Research Foundation NCORP | - | - | - | - | - |
| New Mexico Minority Underserved NCORP | - | - | 2 | 1 | - |
| Northwell Health NCORP | - | - | - | 6 | - |
| Northwestern University LAPS | 1 | - | 6 | 13 | - |
| Ohio State University Comprehensive Cancer Center LAPS | 6 | 4 | 8 | 12 | - |
| Pacific Cancer Research Consortium NCORP | - | - | - | 2 | - |

Melanoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

| | S1512 | S1607 | S1616 | S1801 | S2000 |
|---|-----------|-----------|-----------|------------|-----------|
| SCL Health Saint Joseph Hospital | - | - | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | 1 | - | - | - | - |
| Sutter Cancer Research Consortium | - | - | - | - | - |
| The Don and Sybil Harrington Cancer Center | - | - | - | 2 | - |
| The West Clinic - Wolf River | - | - | 7 | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | - | - | 3 | - |
| UC San Diego Moores Cancer Center | - | - | 2 | - | - |
| UCLA / Jonsson Comprehensive Cancer Center | 4 | 8 | 6 | 5 | - |
| USC Norris Comprehensive Cancer Center LAPS | 5 | 5 | - | 8 | - |
| University of Alabama at Birmingham / Deep South Research Consortium LAPS | - | - | - | 1 | - |
| University of Arkansas for Medical Sciences | - | - | - | - | - |
| University of Cincinnati Cancer Center-UC Medical Center | - | - | - | - | - |
| University of Colorado Cancer Center LAPS | - | - | - | - | - |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 2 | 1 | 2 | 6 | - |
| University of Kentucky/Markey Cancer Center | - | - | - | 2 | - |
| University of Michigan Comprehensive Cancer Center LAPS | - | - | - | 15 | 1 |
| University of Rochester LAPS | - | - | 5 | 4 | - |
| University of Texas Health Science Center at San Antonio | - | - | - | - | - |
| University of Texas MD Anderson Cancer Center LAPS | - | - | - | 10 | - |
| University of Utah - Huntsman Cancer Institute LAPS | 10 | 10 | 1 | 18 | - |
| Vanderbilt University - Ingram Cancer Center LAPS | - | 1 | 1 | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | - | - | - | - |
| Wisconsin NCI Community Oncology Research Program | - | - | 1 | 8 | - |
| Yale University - Yale Cancer Center LAPS | - | - | - | - | - |
| ALLIANCE | 1 | - | 9 | 27 | 1 |
| ECOG-ACRIN | 2 | 8 | 7 | 40 | 2 |
| NRG | 4 | 2 | 13 | 43 | 1 |
| Total | 57 | 43 | 94 | 300 | 10 |

Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2021 Virtual Group Meeting. Conference abstracts are not included.

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

(none this cycle)

Submitted Manuscripts

(none this cycle)

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

(none this cycle)

Submitted Manuscripts

(none this cycle)

BREAST COMMITTEE

Published/Accepted Manuscripts

S1007 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Puzstai L, Hortobagyi GN. *New England Journal of Medicine* Dec 16;385(25):2336-2347:2336-2347, 2021. PMID34914339. <https://pubmed.ncbi.nlm.nih.gov/34914339/>

S1222 A randomized trial of fulvestrant, everolimus and anastrozole in the front line treatment of advanced hormone receptor positive breast cancer, SWOG S1222. Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Puzstai L, Hortobagyi GN. *Clinical Cancer Research*, Nov 29;clincanres. 3131.2021. doi: 10.1158/1078-0432.CCR-21-3131. Online ahead of print., 2021. PMID34844978. <https://pubmed.ncbi.nlm.nih.gov/34844978/>

C40603 CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer

EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. *Journal of Clinical Oncology*. Jan 19;JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print, 2022. PMID35044810 <https://pubmed.ncbi.nlm.nih.gov/35044810/>

MA.32 Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. Goodwin P, O'Dowling R, Ennis M, Chen B, Parulekar W, Shepherd L, Gelmon K, Whelan T, Ligibel J, Hershman D, Mayer I, Hobday T, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson A, Rea D, Stambolic Vuk. *JNCI Cancer Spectrum* Jul 28;5(5):pkab066, 2021. PMID34485814; PMC8410139. <https://pubmed.ncbi.nlm.nih.gov/34485814/>

R9804 Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804. McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, Smith BL, Germain I, Hartford AC, O'Rourke MA, Walker EM, Strom EA, Hopkins JO, Pierce LJ, Pu AT, Sumida KNM, Vesprini D, Moughan J, White JR. *Journal of Clinical Oncology*, Nov 10;39(32):3574-3582, 2021. PMID34406870; PMC8577682 <https://pubmed.ncbi.nlm.nih.gov/34406870/>

Submitted Manuscripts

(none this cycle)

CANCER CONTROL AND PREVENTION COMMITTEES

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

S1417CD S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. Shankaran V, Unger J, Darke A, Suga J, Wade J, Kourlas P, Chandana S, O'Rourke M, Satti S, Liggett D, Hershman D, Ramsey S. *Journal of the National Cancer Institute* Jan 4;djab210. doi: 10.1093/jnci/djab210. Online ahead of print., 2022. PMID34981117. <https://pubmed.ncbi.nlm.nih.gov/34981117/>

Multiple Studies Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Unger J, Vaidya R, Albain K, LeBlanc M, Minasian L, Gotay C, Henry NL, Fisch M, Lee S, Blanke CD, Hershman D. *Journal of Clinical Oncology* Feb 4;JCO2102377. doi: 10.1200/JCO.21.02377. Online ahead of print., 2022. PMID35119908. <https://pubmed.ncbi.nlm.nih.gov/35119908/>

Publication List by Committee

[see also Symptom Control & Quality of Life Cmte]

Caregiver engagement practices in National Cancer Institute Clinical Oncology Research Program settings: Implications for research to advance the field. Nightingale C, Sterba K, McLouth L, Kent E, Dressler E, Dest A, Snaveley A, Adonizio C, Wojtowicz M, Neuman H, Kazak A, Carlos R, Hudson M, Unger JM, Kamen C, Weaver K. *Cancer* Feb 15;127(4):639-647, 2021. PMID33136296; PMC7854890.
<https://pubmed.ncbi.nlm.nih.gov/33136296/>

Submitted Manuscripts

S1415CD S1415CD: Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. Watabayashi K, Bell-Brown A, Kreizenbeck K, Egan K, Lyman G, Hershman D, Arnold K, Bansal A, Barlow WE, Sullivan S, Ramsey S. *BMC Health Services Research*, submitted 2022.

S1204 Antiviral Therapy Use, Changes in Anticancer Treatment, and Adverse Viral Outcomes in Patients with Cancer and Viral Infections: Results from a Multicenter Observational Study (SWOG S1204). Hwang J, Arnold K, Unger J, Chugh R, Tincopa M, Loomba R, Hershman D, Ramsey S. *Supportive Care in Cancer*, submitted 2022..

S1204 Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation. Schwartz N, Unger J, Loomba R, Hwang J, Chugh R, Konerman M, Arnold K, Hershman D, Ramsey S. *American Journal of Preventive Medicine*, submitted 2021.

Multiple Studies Trends in Obesity Prevalence Among Patients Registered to Cancer Clinical Treatment Trials. Vaidya R, Till C, Greenlee H, Hershman D, Unger J. *Cancer*, submitted 2022.

CANCER SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

A011401 The Breast Cancer Weight Loss (BWEL) Trial (Alliance 011401): A Description of the Lifestyle Intervention .Delahanty L, Wadden T, Goodwin P, Alfano C, Thomson C, Irwin M, Neuhaus M, Crane T, Frank E, Spears P, Gillis B, Hershman D, Paskett E, Salem W, Bernstein V, Stearns V, White J, Hudis C, Winer E, Carey L, Partridge A, Ligibel J. *Obesity* Jan;30(1):28-38, 2022. PMID34932888.
<https://pubmed.ncbi.nlm.nih.gov/34932888/>
[see also Prevention & Epidemiology Cmte]

Submitted Manuscripts

(none this cycle)

PALLIATIVE AND END OF LIFE CARE COMMITTEE

Published/Accepted Manuscripts

S1820 Altering Intake and Managing Symptoms (AIMS): Feasibility of a Diet Modification Intervention for Post-Treatment Bowel Dysfunction in Rectal Cancer [S1820 Pilot]. .Sun V, Crane T, Freylersthe S, Slack S, Yung A, Krouse R, Thomson C. *Clinical Journal of Oncology Nursing*, accepted 2022.

Multiple Studies* Association between Health-Related Quality of Life and Progression Free Survival in Patients with Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. Hui D, Darke A, Guthrie K, Subbiah I, Unger J, Hershman D, Krouse R, Bakitas M, O'Rourke M. *JCO Oncology Practice*. Oct 4;OP2100407. doi: 10.1200/OP.21.00407. Online ahead of print, 2021 2021. PMID34606328 [*S0027,S0421,S9509]
<https://pubmed.ncbi.nlm.nih.gov/34606328/>

Submitted Manuscripts

(none this cycle)

PREVENTION AND EPIDEMIOLOGY COMMITTEE

Published/Accepted Manuscripts

S0000/Other A 584bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion, and confers risk of pancreatic cancer. Jermusyk A, Zhong J, Connelly K, Gordon N, Perera S, Abdolizadeh E, Zhang T, O'Brien A, Hoskins J, Collins I, Eiser D, Yuan C, PanScan Consortium [Goodman P, collaborator], PanC4 Consortium, Risch H, Jacobs E, Li D, Du M, Stolzenberg-Solomon R, Klein A, Smith J, Wolpin B, Chanock S, Shi J, Petersen G, Westlake C, Amundadottir L. *American Journal of Human Genetics*, Oct 7;108(10):1852-1865, 2021. PMID34559995; PMC8546220
<https://pubmed.ncbi.nlm.nih.gov/34559995/>

S0000/Other Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers. Yarmolinsky J, Diez-Obrero V, Richardson T, Pigeyre M, Sjaarda J, Pare G, Walker V, Vincent E, Tan V, Obon-Santacana M, Albanes D, Hampe J, Gsur A, Hampel H, Kampman E, Pai R, Jenkins M, Gallinger S, Zheng W, Amos C, Internataional Lung Cancer Consortium, PRACTICAL Consortium] Tangen CJ, MEGASTROKE Consortium, Davey G, Martin R, Moreno V. *PLOS Medicine* Feb 3;19(2):e1003897. doi: 10.1371/journal.pmed.1003897. eCollection 2022 Feb., 2022. PMID35113855; PMC8812899.
<https://pubmed.ncbi.nlm.nih.gov/35113855/>

Publication List by Committee

S0000C Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function Decline and with CYP4F2 Missense Variation. Xu J, Guertin K, Gaddis N, Agler A, Parker R, Feldman J, Kristal A, Arnold K, Goodman P, Tangen C, Hancock D, Cassano P. *American Journal of Clinical Nutrition*, Jan 18;nqac013. doi: 10.1093/ajcn/nqac013. Online ahead of print. 2022. PMID35040869 <https://pubmed.ncbi.nlm.nih.gov/35040869/>

S9217 Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Gong Z, Platek ME, Till C, Goodman PJ, Tangen CM, Platz EA, Neuhaus ML, Thompson IM, Santella RM, Ambrosone CB. *Frontiers in Oncology* Jan 14;11:808715, 2022.PMID35096612; PMC8795906 <https://pubmed.ncbi.nlm.nih.gov/35096612/>

S9217 Serum Markers, Obesity and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Chau C, Till C, Price D, Goodman P, Neuhaus M, Pollak M, Thompson I, Figg W. *Endocrine-Related Cancer* Jan 20;29(2):99-109, 2022. PMID34889205; PMC8776589. <https://pubmed.ncbi.nlm.nih.gov/34889205/>

S9217/Other Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, Parent MÉ, Hu JJ, Zheng W; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium, Mills IG, Andreassen OA, Dale AM, Seibert TM. *Prostate Cancer and Prostatic Diseases* Feb 12. doi: 10.1038/s41391-022-00497-7, 2022. PMID: 35152271. <https://pubmed.ncbi.nlm.nih.gov/35152271/>

S9217/Other Advancing traditional PSA kinetics in the detection of prostate cancer: A Machine Learning model. Perera M, Smith L, Thompson IM, Breemer J, Pappa N, Patel M, Patel M, Swindle P, Smith E. *European Urology Focus* Dec 14;:S2405-4569(21)00309-6, 2021.

PMID34920976. <https://pubmed.ncbi.nlm.nih.gov/34920976/>

Multiple Studies* The relationship between lipoprotein A and prostate cancer risk: A multivariable Mendelian randomization study. Ioannidou A, Watts E, Perez-Cornago A, Platz E, Mills I, Key T, Travis R, The PRACTICAL consortium [C Tangen Contributor], CRUK, BPC3, CAPS, PEGASUS, Tsilidis K, Zuber V. *PLOS Medicine* Jan 27;19(1):e1003859. doi: 10.1371/journal.pmed.1003859. eCollection 2022 Jan, 2022. [*S0000,S9217,Other] PMID35085228; PMC8794090. <https://pubmed.ncbi.nlm.nih.gov/35085228/>

Multiple Studies* A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Darst B, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Klein E, Goodman P, Thompson I, Rebbeck T, Conti D, Haiman C. *European Urology* Jan 11;S0302-2838(21)02271-5. doi: 10.1016/j.eururo.2021.12.023. Online ahead of print, 2022. PMID35031163 [*S0000,S9217,Other] <https://pubmed.ncbi.nlm.nih.gov/35031163/>

Multiple Studies* Circulating Inflammatory Cytokines and Risk of Five Cancers: a Mendelian Randomization Analysis. Bouras E, Karhunen V, Huang J, Gill D, Brennan P, Gunter M, Haycock P, Johansson M, Key T, Lewis S, Martin R, Mengaux F, Murphy N, Platz E, Travis R, Truong T, Yarmolinsky J, Jarvelin M-R, Dehghan A, Tsilidis K, [C Tangen Contributor]. *BMC Medicine* Jan 11;20(1):3, 2022. [*S0000,S9217,Other] PMID35012533; PMC8750876. <https://pubmed.ncbi.nlm.nih.gov/35012533/>

A011401 The Breast Cancer Weight Loss (BWEL) Trial (Alliance 011401): A Description of the Lifestyle Intervention. Delahanty L, Wadden T, Goodwin P, Alfano C, Thomson C, Irwin M, Neuhaus M, Crane T, Frank E, Spears P, Gillis B, Hershman D, Paskett E, Salem W, Bernstein V, Stearns V, White J, Hudis C, Winer E, Carey L, Partridge A, Ligibel J. *Obesity* Jan;30(1):28-38, 2022. PMID34932888. <https://pubmed.ncbi.nlm.nih.gov/34932888/> [see also Cancer Survivorship Cmte]

Submitted Manuscripts

S0000/Other Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials. Gelfond J, Hernandez B, Goros M, Ibrahim J, Chen M, Sun W, Liss M, Leach R, Thompson I, Ankerst D. *World Journal of Urology*, under review .

S0000/Other Accommodating population differences in model validation. Pfeiffer R, Chen Y, Gail M, Ankerst D. *Statistics in Medicine*, under review.

S0000/Other Dysregulated super-enhancers in colorectal cancer are

Publication List by Committee

beacons for discovering genetic risk loci. Bien S, Harrison T, Huyghe J, Lu Y, Wang H, Shcherbina A, Albanes D, Goodman P, Platz E, Tangen C, Le Marchang L, Zheng W, Gruber S, Hsu L, Schacheri P, Peters U. Nature Communications, under review.

S0000/Other Shedding light on the association between genetically-defined BMI and early-onset colorectal cancer in a pooled analysis [Brief Communication]. Archambault A, Gruber S, Le Marchand L, Hsu L, Peters U, Hayes R, on behalf of the Colorectal Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CCFR), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) [P Goodman, C Tangen, GECCO collaborators]. Gastroenterology, under review .

Multiple Studies* A prostate cancer susceptibility PSA variant that confers lower risk is also associated with more aggressive disease and poor survival. Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Rohl J, Perry-Keene J, Buzacott K, Gago M, Schleutker J, Maier C, Muir K, Tangen C, Gronberg H, Pashayan N, Albanes D, Wolk A, Eles R, Clements J, Batra J. Cancer Discovery, under review.[*S0000, S9217, OTHER]

SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE

Published/Accepted Manuscripts

B35 Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Henry NL, Kim S, Hays R, Diniz M, Luu M, Cecchini R, Yothers G, Rogatko A, Ganz P. Toxicity Index, Journal of Clinical Oncology, Dec 1;39(34):3800-3812, 2021. PMID34554865. <https://pubmed.ncbi.nlm.nih.gov/34554865>

Multiple Studies* Predictors of pain reduction in trials of interventions for aromatase inhibitor-associated musculoskeletal symptoms. Henry NL, Unger JM, Till C, Crew KD, Fisch MJ, Hershman DL, JNCI Cancer Spectrum Oct 30;5(6):pkab087, 2021. PMID34901744; PMC8660068. [*S0927, S1200, S1202]. <https://pubmed.ncbi.nlm.nih.gov/34901744/>

Multiple Studies Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Unger J, Vaidya R, Albain K, LeBlanc M, Minasian L, Gotay C, Henry NL, Fisch M, Lee S, Blanke CD, Hershman D. Journal of Clinical Oncology Feb 4;JCO2102377. doi: 10.1200/JCO.21.02377. Online ahead of print., 2022. PMID35119908. <https://pubmed.ncbi.nlm.nih.gov/35119908/> [see also CCD Cmte]

Submitted Manuscripts

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Prostate Cancer and Prostatic Diseases, under review. [see also GU cmte]

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Journal of Patient Reported Outcomes, under review. [see also GI Committee]

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

(none this cycle)

Submitted Manuscripts

(none this cycle)

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Adams S, Othus M, Patel S, Miller K, Chugh R, Schuetz S, Chamberlin M, Haley B, Storniolo A, Cawley K, Reddy M, Anderson S, Zimmerman C, O'Dea A, Mirshahidi M, Ahnert J, Brescia F, Hahn O, Raymond J, Biggs D, Thompson M, Connolly R, Sharon E, Korde L, Gray R, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. Clinical Cancer Research Jan 15;28(2):271-278, 2022. PMID34716198;PMC8776596 <https://pubmed.ncbi.nlm.nih.gov/34716198/>

Submitted Manuscripts

(none this cycle)

Publication List by Committee

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

- S1513** Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Chiorean EG, Guthrie K, Philip P, Swisher E, Jalikis F, Pishvaian M, Berlin J, Noel M, Suga J, Garrido-Laguna I, Cardin D, Radke M, Duong M, Lowy A, Hochster H. *Clinical Cancer Research*, Dec 1;27(23):6314-6322, 2021. PMID34580114; PMC8639715. <https://pubmed.ncbi.nlm.nih.gov/34580114/>
- C80405** Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Arai H, Elliott A, Millstein J, Xiu J, Ou F-S, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg R, Hall M, Scott A, Khushman M, Hwang J, Lou E, Weinberg B, Lockhart A, Shields A, Abraham J, Magee D, Stafford P, Zhang J, Venook A, Venook A, Korn W, Lenz H-J. *Oncogene* Jan;41(2):260-267, 2022. PMID34728807; PMC8738154. <https://pubmed.ncbi.nlm.nih.gov/34728807/>
- C80405** Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance). Innocenti F, Sibley A, Patil S, Etheridge A, Jiang C, Ou F-S, Denning S, Casey G, Bertagnolli M, McLeod H, Auman T, Blanke CD, Furukawa Y, Venook A, Kubo M, Lenz H-J, Parker J, Ratain M, Owzar K. *Clinical Cancer Research* Jan 1;27(1):267-275, 2021. PMID32958699; PMC7785628. <https://pubmed.ncbi.nlm.nih.gov/32958699/>
- C80405** Survival of Patients with Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. Lipsyc-Sharf M, Zhang S, Ou F, Jackson McCleary N, Niedzwiecki D, Chang I, Lenz H-J, Blanke CD, Piawah S, Van Loon K, Bainter T, Venook A, Mayer R, Fuchs C, Innocenti F, Nixon A, Goldberg R, O'Reilly E, Meyerhardt J. *Journal of the National Cancer Institute* Oct 12;djab200. doi: 10.1093/jnci/djab200. Online ahead of print, 2021. PMID34636852. <https://pubmed.ncbi.nlm.nih.gov/34636852/>
- C80405** Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer of CALGB/SWOG 80405 (Alliance) treated with standard-of-care combinations of bevacizumab and cetuximab. Innocenti F, Yazdani A, Rashid N, Qu X, Ou F-S, Van Buren S, Bertagnolli M, Kabbarah O, Blanke C, Venook A, Lenz H-J, Vincent B. *Clinical Cancer Research* Feb 17;clinres.3202. 2021. doi: 10.1158/1078-0432.CCR-21-3202. Online ahead of print, 2022. PMID35176136. <https://pubmed.ncbi.nlm.nih.gov/35176136/>
- C80405** Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. *Journal of Geriatric Oncology* Jan 29;S1879-4068(22)00007-8, 2022. PMID35105521 <https://pubmed.ncbi.nlm.nih.gov/35105521/>
- C80405** Plasma protein biomarkers predictive of benefit from bevacizumab versus cetuximab in colorectal cancer: Results from CALGB 80405 (Alliance). Nixon A, Sibley A, Liu Y, Hatch A, Jiang C, Mulkey F, Starr M, Brady J, Niedzwiecki D, Venook A, Hochster H, Lenz H-J, O'Neil B, Meyerhardt J, O'Reilly E, Owzar K, Innocenti F, Hurwitz H. *Clinical Cancer Research* Dec 29. doi: 10.1158/1078-0432.CCR-21-2389. Online ahead of print, 2021. PMID34965954. <https://pubmed.ncbi.nlm.nih.gov/34965954/>
- C80702** Early-Onset Colorectal Adenocarcinoma in the IDEA database: Treatment Adherence, Toxicities and Outcomes with 3 and 6 months of Adjuvant Fluoropyrimidine and Oxaliplatin. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth E, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, Andre T, Yamanaka T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E, Georgoulis V, Ben-Aharon I, Shi Q. *Journal of Clinical Oncology* Dec 20;39(36):4009-4019, 2021. PMID34752136; PMC8677996. <https://pubmed.ncbi.nlm.nih.gov/34752136/>
- C89803** Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Stage III Colon Cancer Patients (Alliance). Cheng E, Ma C, Spiegelman D, Zhou X, Ou F, Niedzwiecki D, Mayer R, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci E, Van Blarigan E, Ng K, Gross C, Meyerhardt J, Fuchs C. *Journal of Clinical Oncology*, Jan 7;JCO2101784. doi: 10.1200/JCO.21.01784. Online ahead of print, 2022. PMID34995084 <https://pubmed.ncbi.nlm.nih.gov/34995084/>
- Multiple Studies*** Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens. Quintanilha J, Wang J, Sibley A, Xu W, Espin-Garcia O, Jiang C, Etheridge A, Ratain M, Lenz H-J, Bertagnolli M, Kindler H, Dickler M, Venook A, Liu J, Owzar K, Lin D, Innocenti F. *International Journal of Cancer*, Jan 15;150(2):279-289, 2022. PMID34528705. [*C40503,C80303,C80405,OTHER] <https://pubmed.ncbi.nlm.nih.gov/34528705/>
- R1010** Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG

Publication List by Committee

1010): a multicentre, randomised, phase 3 trial. Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick M, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Moughan J, Crane CH. *Lancet Oncology* Feb;23(2):259-269, 2022. PMID35038433
<https://pubmed.ncbi.nlm.nih.gov/35038433/>

Submitted Manuscripts

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. *Journal of Patient Reported Outcomes*, under review. [see also SCQOL Cmte]

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S1602/S8507 The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer [Editorial]. Li R, Lerner SP, Kamat AM. *European Urology* Apr;79(4):437-439, 2021. PMID33454163
<https://pubmed.ncbi.nlm.nih.gov/33454163/>

S1806/Other Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer [Seminars Article; Review]. Ballas L, Singh P, Lerner SP. *Urologic Oncology* Nov 2;:S1078-1439(20)30478-6, 2020. PMID33153882. [NB: correction to previously reported citation]. <https://pubmed.ncbi.nlm.nih.gov/33153882/>

S8710/Other Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. McCaw ZR, Odisho AY, Chaparala H, Yin M, Cloyd J, Svatek RS, Carson WE, Lee CT, Sundi D. *Urologic Oncology* (Seminars and Original Investigations) Jul;39(7):435.e17-435.e22, 2021. PMID: 33436327
<https://pubmed.ncbi.nlm.nih.gov/33436327/>

Submitted Manuscripts

S1216 Orteronel for Metastatic Hormone Sensitive Prostate Cancer. Agarwal N, Tangen C, Hussain M, Gupta S, Plets M, Lara P, Harzstark A, Twardowski P, Paller C, Zylla D, Zibelman M, Levine E, Roth B, Goldkorn A, Vaena D, Kohli M, Crispino A, Vogelzang N, Thompson IM, Quinn DI. *Journal of Clinical Oncology*, submitted.

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. *Prostate Cancer and Prostatic Diseases*, under review. [see also SCQOL cmte]

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

S1318 SWOG 1318: A Phase 2 Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Advani A, Moseley A, O'Dwyer K, Wood B, Fang M, Wieduwilt M, Aldoss I, Park J, Klisovic R, Baer M, Stock W, Bhawe R, Othus M, Harvey R, Willman C, Litzow M, Stone R, Sharon E, Erba H. *Journal of Clinical Oncology*, Feb 14;JCO2101766. doi: 10.1200/JCO.21.01766. Online ahead of print, 2022. PMID: 35157496 <https://pubmed.ncbi.nlm.nih.gov/35157496/>

C10701 Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Wieduwilt M, Yin J, Wetzler M, Uy G, Powell B, Kolitz J, Liedtke M, Stock W, Beumer J, Mattison R, Storrack E, Christner S, Lewis L, Devine S, Stone R, Larson R. *Blood Advances*, Nov 23;5(22):4691-4700, 2021. PMID34492682; PMC8759134. <https://pubmed.ncbi.nlm.nih.gov/34492682/>

E2902 Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. *Leukemia Research* Dec;111:106736, 2021. PMID34773794; PMC8643322.
<https://pubmed.ncbi.nlm.nih.gov/34773794/>

Multiple Studies* A precision medicine classification for treatment of acute myeloid leukemia in older patients Mims A, Kohlschmidt J, Borate U, Blachly J, Orwick S, Eisfeld K, Papaioannou D, Nicolet D, Mrozek K, Stein E, Bhatnagar B, Stone R, Kolitz J, Wang E, Powell B, Burd A, Levine R, Druker B, Bloomfield C, Byrd J. *Journal of Hematology & Oncology* Jun 23;14(1):96, 2021. [*C10201, C10502, C11001, C11002, C1801, C20202, C8461, C9720]. PMID34162404; PMC8220739.
<https://pubmed.ncbi.nlm.nih.gov/34162404/>

Publication List by Committee

Submitted Manuscripts

S1203 Standard versus high-dose cytarabine with or without vorinostat for AML. Garcia-Manero G, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland SA, Litzow MR, Savoie M, Medeiros B, Sekeres M, Lin TL, Uy G, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba HP. Leukemia, resubmitted/under review, 2022.

LUNG COMMITTEE

Published/Accepted Manuscripts

S0819 EGFR High Copy Number Together with High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis from SWOG S0819, a phase III trial of chemotherapy with or without Cetuximab in advanced NSCLC. Hirsch FR, Redman MW, Moon J, Augustino F, Herbst RS, Semrad T, Varella Garcia M, Rivard C, Kelly K, Gandara DR, Mack PC. Clinical Lung Cancer, Jan;23(1):60-71,2022. PMID34753703; PMC8766941 <https://pubmed.ncbi.nlm.nih.gov/34753703/>

Submitted Manuscripts

S1403 Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Mack P, Miao J, Redman MW, Moon J, Goldberg S, Herbst RS, Melnick M, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Cancer Discovery, submitted 2022.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S1918 SWOG 1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Brem E, Li H, Beaven A, Caimi P, Cerchiatti L, Alizadeh A, Olin R, Henry NL, Dillon H, Little R, Laubach C, LeBlanc M, Friedberg JW, Smith S. Journal of Geriatric Oncology, Oct 19;S1879-4068(21)00235-6. doi: 10.1016/j.jgo.2021.10.003. Online ahead of print, 2021. PMID34686472. <https://pubmed.ncbi.nlm.nih.gov/34686472/>

Submitted Manuscripts

Multiple Studies* Extranodal presentation in limited stage DLBCL as a prognostic marker in three SWOG trials S0014, S0313 and S1001 [Letter to Editor]. Stephens D, Li H, Constine L, Fitzgerald T, Leonard J, Kahl B, LeBlanc M, Smith S, Friedberg JW, Persky D. Blood, under review 2022. [*S0014,S0313,S1001]

Multiple Studies* Relevance of bone marrow biopsies for response assessment in U.S. National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials. Rutherford S, Yin J, Pederson L, Perez Burbano G, LaPlant P, Shadman M, Li H, LeBlanc M, Kenkre V, Hong F, Blum K, Dockter T, Martin P, Jung S, Grant B, Rosenbaum C, Ujjani C, Barr P, Unger J, Cheson B, Bartlett N, Kahl B, Friedberg JW, Mandrekar S, Leonard J. Journal of Clinical Oncology, under revision for resubmission, 2022. [*S0016,S0801, and CALGB studies (Alliance-led)]

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S0438/S0512 Accounting for All Patients in Waterfall Plots. Moon J, LeBlanc M, Othus M. JCO Clinical Cancer Informatics Apr;5:414-420, 2021. PMID33830787; PMC8240789 <https://pubmed.ncbi.nlm.nih.gov/33830787/>

S1404 Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. Grossmann K, Othus M, Patel S, Tarhini A, Sondak V, Knopp M, Petrella T, Truong T-G, Khushalani N, Cohen J, Buchbinder E, Kendra K, Funchain P, Lewis K, Conry R, Chmielowski B, Kudchadkar R, Johnson D, Li H, Moon J, Eroglu J, Gastman B, Kovacovics M, Gunturu K, Ebbinghaus S, Ahsan S, Ibrahim N, Sharon E, Korde L, Kirkwood J, Ribas A. Cancer Discovery Nov 11;candisc.1141.2021. doi: 10.1158/2159-8290.CD-21-1141. Online ahead of print., 2021. PMID34764195. <https://pubmed.ncbi.nlm.nih.gov/34764195/>

Submitted Manuscripts

S0826 SWOG S0826: A phase II trial of SCH 727965 (NSC727135, dinaciclib) in patients with stage IV melanoma. Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak V. BMC Cancer, submitted 2022.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

Survey of US Medical Oncologists? Practices and Beliefs regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Koo K, Pasternak A, Henry NL, Sahai V, Hertz D. Journal of Oncology Practice, 2022.

Submitted Manuscripts

(none this cycle)

Thanks to our
meeting exhibitors!

Bayer

Daiichi Sankyo

Janssen Oncology

Novartis

IROC